<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury - Chen, H - 2020 | Cochrane Library</title> <meta content="Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury - Chen, H - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010904.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury - Chen, H - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010904.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010904.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury" name="citation_title"/> <meta content="Han Chen" name="citation_author"/> <meta content="Third Xiangya Hospital, Central South University" name="citation_author_institution"/> <meta content="75517886@qq.com" name="citation_author_email"/> <meta content="Zhi Song" name="citation_author"/> <meta content="Third Xiangya Hospital, Central South University" name="citation_author_institution"/> <meta content="Jane A Dennis" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010904.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/01/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010904.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010904.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010904.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Brain Injuries [*complications]; Brain Injuries, Traumatic [*complications]; Glasgow Outcome Scale; Intracranial Hypertension [*drug therapy]; Intracranial Pressure [*drug effects]; Randomized Controlled Trials as Topic; Saline Solution, Hypertonic [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010904.pub3&amp;doi=10.1002/14651858.CD010904.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010904\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010904\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa","pt","zh_HANT","ms","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010904.pub3",title:"Hypertonic saline versus other intracranial pressure\\u2013lowering agents for people with acute traumatic brain injury",firstPublishedDate:"Jan 17, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010904.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010904.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010904.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010904.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010904.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010904.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010904.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010904.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010904.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010904.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>64858 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010904.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/appendices#CD010904-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/table_n/CD010904StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/table_n/CD010904StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information#CD010904-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Han Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information#CD010904-cr-0003">Zhi Song</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information#CD010904-cr-0004">Jane A Dennis</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information/en#CD010904-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 January 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010904.pub3">https://doi.org/10.1002/14651858.CD010904.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010904-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010904-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010904-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010904-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010904-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010904-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010904-abs-0001" lang="en"> <section id="CD010904-sec-0001"> <h3 class="title" id="CD010904-sec-0001">Background</h3> <p>Increased intracranial pressure has been shown to be strongly associated with poor neurological outcomes and mortality for patients with acute traumatic brain injury. Currently, most efforts to treat these injuries focus on controlling the intracranial pressure. Hypertonic saline is a hyperosmolar therapy that is used in traumatic brain injury to reduce intracranial pressure. The effectiveness of hypertonic saline compared with other intracranial pressure‐lowering agents in the management of acute traumatic brain injury is still debated, both in the short and the long term. </p> </section> <section id="CD010904-sec-0002"> <h3 class="title" id="CD010904-sec-0002">Objectives</h3> <p>To assess the comparative efficacy and safety of hypertonic saline versus other intracranial pressure‐lowering agents in the management of acute traumatic brain injury. </p> </section> <section id="CD010904-sec-0003"> <h3 class="title" id="CD010904-sec-0003">Search methods</h3> <p>We searched Cochrane Injuries' Specialised Register, CENTRAL, PubMed, Embase Classic+Embase, ISI Web of Science: Science Citation Index and Conference Proceedings Citation Index‐Science, as well as trials registers, on 11 December 2019. We supplemented these searches with searches of four major Chinese databases on 19 September 2018. We also checked bibliographies, and contacted trial authors to identify additional trials. </p> </section> <section id="CD010904-sec-0004"> <h3 class="title" id="CD010904-sec-0004">Selection criteria</h3> <p>We sought to identify all randomised controlled trials (RCTs) of hypertonic saline versus other intracranial pressure‐lowering agents for people with acute traumatic brain injury of any severity. We excluded cross‐over trials as incompatible with assessing long‐term outcomes. </p> </section> <section id="CD010904-sec-0005"> <h3 class="title" id="CD010904-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened search results to identify potentially eligible trials and extracted data using a standard data extraction form. Outcome measures included: mortality at end of follow‐up (all‐cause); death or disability (as measured by the Glasgow Outcome Scale (GOS)); uncontrolled intracranial pressure (defined as failure to decrease the intracranial pressure to target and/or requiring additional intervention); and adverse events e.g. rebound phenomena; pulmonary oedema; acute renal failure during treatment). </p> </section> <section id="CD010904-sec-0006"> <h3 class="title" id="CD010904-sec-0006">Main results</h3> <p>Six trials, involving data from 287 people, met the inclusion criteria. The majority of participants (91%) had a diagnosis of severe traumatic brain injury. We had concerns about particular domains of risk of bias in each trial, as physicians were not reliably blinded to allocation, two trials contained participants with conditions other than traumatic brain injury and in one trial, we had concerns about missing data for important outcomes. The original protocol was available for only one trial and other trials (where registered) were registered retrospectively. </p> <p>Meta‐analysis for both the primary outcome (mortality at final follow‐up) and for 'poor outcome' as per conventionally dichotomised GOS criteria, was only possible for two trials. Synthesis of long‐term outcomes was inhibited by the fact that two trials ceased data collection within two hours of a single bolus dose of an intracranial pressure‐lowering agent and one at discharge from the intensive care unit (ICU). Only three trials collected data after participants were released from hospital, one of which did not report mortality and reported a 'poor outcome' by GOS criteria in an unconventional way. Substantial missing data in a key trial meant that in meta‐analysis we report 'best‐case' and 'worst‐case' estimates alongside available case analysis. In no scenario did we discern a clear difference between treatments for either mortality or poor neurological outcome. </p> <p>Due to variation in modes of drug administration (including whether it followed or did not follow cerebrospinal fluid (CSF) drainage, as well as different follow‐up times and ways of reporting changes in intracranial pressure, as well as no uniform definition of 'uncontrolled intracranial pressure', we did not perform meta‐analysis for this outcome and report results narratively, by individual trial. Trials tended to report both treatments to be effective in reducing elevated intracranial pressure but that hypertonic saline had increased benefits, usually adding that pretreatment factors need to be considered (e.g. serum sodium and both system and brain haemodynamics). No trial provided data for our other outcomes of interest. We consider evidence quality for all outcomes to be very low, as assessed by GRADE; we downgraded all conclusions due to imprecision (small sample size), indirectness (due to choice of measurement and/or selection of participants without traumatic brain injury), and in some cases, risk of bias and inconsistency. </p> <p>Only one of the included trials reported data on adverse effects; a rebound phenomenon, which was present only in the comparator group (mannitol). None of the trials reported data on pulmonary oedema or acute renal failure during treatment. On the whole, trial authors do not seem to have rigorously sought to collect data on adverse events. </p> </section> <section id="CD010904-sec-0007"> <h3 class="title" id="CD010904-sec-0007">Authors' conclusions</h3> <p>This review set out to find trials comparing hypertonic saline to a potential range of other intracranial pressure‐lowering agents, but only identified trials comparing it with mannitol or mannitol in combination with glycerol. Based on limited data, there is weak evidence to suggest that hypertonic saline is no better than mannitol in efficacy and safety in the long‐term management of acute traumatic brain injury. Future research should be comprised of large, multi‐site trials, prospectively registered, reported in accordance with current best practice. Trials should investigate issues such as the type of traumatic brain injury suffered by participants and concentration of infusion and length of time over which the infusion is given. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010904-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010904-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010904-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010904-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010904-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010904-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010904-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010904-abs-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010904-abs-0010">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010904-abs-0004" lang="en"> <h3>Concentrated salt solution versus other treatments to lower pressure around the brain for people with acute traumatic brain injury </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence for the effectiveness and safety of infusions (where a substance is given through a vein) of hypertonic saline (concentrated salt (sodium chloride) solution) compared with other types of infusion for lowering intracranial pressure (pressure in and around the brain) in the management of acute traumatic brain injury. </p> <p><b>Background</b> </p> <p>Acute traumatic brain injury (sudden and severe injury to the brain, often due to accidents) is a leading cause of death and disability worldwide, especially in children and young people. Intracranial hypertension (the build‐up of high pressure within and around the brain) is common after damage to the brain. This is because the skull is a rigid compartment that contains three parts: soft brain tissue, blood, and cerebrospinal fluid. If an increase occurs in the volume of one component, such as hematomas (collections of blood) within the brain's soft tissue, the volume of one or more of the other components must decrease ‐ otherwise intracranial pressure will rise. If intracranial pressure increases beyond certain limits, there is an imbalance, and blood flow to the brain becomes dangerously low. This high intracranial pressure can cause serious effects that include brain damage and death. Hyperosmolar therapy is an important treatment for raised intracranial pressure. One kind of hyperosmolar therapy involves an infusion of concentrated (hypertonic) saline (table salt/sodium chloride) solution into the blood; other treatments including mannitol (a form of sugar) can also be used. Such treatments may lower intracranial pressure by reducing water volume inside and between brain cells. </p> <p><b>Trial characteristics</b> </p> <p>In December 2019, the authors of this review searched for randomised trials comparing the effects and safety of hypertonic saline with other fluid infusions that are used to lower intracranial pressure in people with acute traumatic brain injury. The review authors searched a wide variety of medical databases and identified six relevant trials, with data from a total of 287 participants. The trials were all randomised controlled trials, which produce the most reliable evidence. Three trials took place in India, one each in France and Germany, and one included people from both France and Israel. Most people in the trials (91%) had traumatic brain injury. Trials compared various concentrations of hypertonic saline with either mannitol or mannitol in combination with glycerol. </p> <p><b>Key results</b> </p> <p>Based on limited data of these six trials, there is no clear evidence to support the use of hypertonic saline infusion over mannitol infusion for people with acute traumatic brain injury. Adverse effects of the treatments were not routinely measured. </p> <p>More research is needed. Future trials should be larger and better reported. Potential points for research include investigating whether there is a particular concentration of infusion, or length of time over which the infusion is given, that benefits people with raised intracranial pressure after traumatic brain injury. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010904-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010904-sec-0108">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010904-sec-0180">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010904-sec-0108"></div> <h3 class="title" id="CD010904-sec-0109">Implications for practice</h3> <section id="CD010904-sec-0109"> <p>We identified six trials suitable for inclusion in this review; all compared a type of hypertonic saline with mannitol or mannitol combined with glycerol; all evidence was of low or very low quality. Trial authors noted that where immediate benefits of hypertonic saline are suggested, they do not translate into long‐term benefit. Therefore at present, there is not sufficient evidence to enable conclusions to be drawn about the efficacy and safety of hypertonic saline versus mannitol or other intracranial pressure‐lowering agents in the management of acute traumatic brain injury. </p> </section> <h3 class="title" id="CD010904-sec-0110">Implications for research</h3> <section id="CD010904-sec-0110"> <p>Carefully planned, high‐quality randomised controlled trials are warranted. We are concerned that searches of trials registers for this review have revealed several terminated trials in this field, but are pleased also to have identified an ongoing trial of adequate size (<a href="./references#CD010904-sec-0139" title="">Characteristics of ongoing studies</a>).<br/> <br/> Future investigators should consider implications of such experiences. The following factors are relevant. </p> <p> <ul id="CD010904-list-0012"> <li> <p>Due to the different definitions of 'uncontrolled intracranial pressure' within identified trials and important differences in reporting intracranial pressure changes from baseline, a widely uniform definition for raised intracranial pressure and intracranial pressure control is necessary. Recently, ESCIM have suggested using a predefined trigger for starting osmotherapy to treat elevated intracranial pressure, and they also suggest using an intracranial pressure threshold above 25 mmHg, independent of other variables, as a trigger for starting osmotherapy to reduce intracranial pressure (<a href="./references#CD010904-bbs2-0070" title="OddoM , PooleD , HelbokR , MeyfroidtG , StocchettiN , BouzatP , et al. Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. Intensive Care Medicine2018;44(4):449‐63. ">Oddo 2018</a>). </p> </li> <li> <p>Consideration should be paid to assessing optimal concentration and infusion time of any intracranial pressure‐lowering agent. </p> </li> <li> <p>Investigators should collect and report data on types of traumatic brain injury experienced by participants (e.g. extradural haematoma, diffuse axonal injury) </p> </li> <li> <p>To test the effect of hypertonic saline on death and neurological recovery for acute traumatic brain injury but not just on intracranial pressure control, longer‐term follow‐up than most of the published trials in this area currently provide, is essential. </p> </li> <li> <p>Trials must be pre‐registered and transparent, and reasonably detailed protocols should be made available. Failure to do so will, in future, result in exclusion of data from this review, in accordance with Cochrane Injuries' policies (<a href="./references#CD010904-bbs2-0042" title="Cochrane Injuries Group. Cochrane Injuries Group Editorial Policy. injuries.cochrane.org/editorial‐policy‐20152015. ">CIG 2015</a>). </p> </li> <li> <p>Results of trials should be reported according to CONSORT (<a href="./references#CD010904-bbs2-0067" title="MoherD , HopewellS , SchulzK , MontoriV , GøtzscheP , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery2010;340:28‐55. ">Moher 2010</a>). </p> </li> <li> <p>Failure to generate a truly informative sample size is an ethical as well as a procedural problem. To combat difficulties in recruitment and attaining a necessary sample size, the possibility of multicentre trials could be considered. </p> </li> <li> <p>Acknowledging obvious recruitment difficulties within this field, in order not to waste valuable data from persistent 'mixed population' trials, investigators could be encouraged to report outcomes disaggregated by type of neurological complaint, for example, stroke or traumatic brain injury. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010904-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010904-sec-0029"></div> <div class="table" id="CD010904-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hypertonic saline compared with other intracranial pressure‐lowering agents for acute traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with other intracranial pressure‐lowering agents for acute traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute traumatic brain injury </p> <p><b>Settings:</b> intensive care units </p> <p><b>Intervention:</b> hypertonic saline (between 3% and 7.5% solution) delivered by infusions </p> <p><b>Comparison:</b> all other intracranial pressure‐lowering agents eligible (but mannitol infusions the sole comparator within the included trials) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (RCTs)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Other intracranial pressure‐lowering agents (mannitol or mannitol with glycerol)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hypertonic saline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> (short‐term) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>2 RCTs reported mortality in the short term, prior to discharge from hospital.</p> <p>Meta‐analysis was not possible.<br/> 1 RCT (n = 38) reported that 3/18 participants in the HTS group and 1/20 in the mannitol group died in the first 6 days following treatment, after which no further deaths occurred in the HTS group but a further 9 deaths occurred in the mannitol group prior to discharge. At this time point, there is a slight trend favouring HTS compared to mannitol (RR 0.33, 95% 0.11 to 1.02). </p> <p>The other RCT (n = 32, in which only a third of participants had TBI) reported that 7/17 (41.2%) participants in the HTS group and 9/15 (60%) in the mannitol group died by the end of stay in the ICU. Here, HTS did not reduce all‐cause mortality in people with acute TBI (RR 0.69, 95% CI 0.34 to 1.39). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not advisable to pool data due to difference in time of assessment and in populations</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> at 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35.6% risk (available case)</p> <p>35.6% risk (worst case for intervention, HTS)</p> <p>44.4% risk (best case for intervention, HTS)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30% risk (available case)</p> <p>40% risk (worst case for intervention, HTS)</p> <p>30% risk (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84 (0.46 to 1.55) (available case)</p> <p>RR 1.12 (0.66 to 1.89) (worst case for intervention, HTS)</p> <p>RR 0.67 (0.38 to 1.18) (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooling done with available, best‐case and worst‐case scenarios. In no case do results show a clear difference between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Glasgow Outcome Scale: poor outcome</b> </p> <p>at 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66.7% risk (available case)</p> <p>66.7% risk (worst case for intervention, HTS)</p> <p>75.6% risk (best case for intervention, HTS)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72.5% risk (available case)</p> <p>82.5% risk (worst case for intervention, HTS)</p> <p>72.5% risk (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09 (0.82 to 1.44) (available case)</p> <p>RR 1.24 (0.97 to 1.58) (worst case for intervention, HTS)</p> <p>RR 0.96 (0.74 to 1.24) (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooling done with available, best‐case and worst‐case scenarios from two studies which supplied sufficient data. </p> <p>One study on children reported GOS non‐traditionally (defining 'poor outcome' as survival with any level of disability excluding persistent vegetative state and found no clear difference between groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Uncontrolled ICP</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>HTS vs mannitol</b> </p> <p>1 RCT reported a difference in the magnitude of ICP reduction and found both HTS and mannitol effectively and equally reduced ICP levels with subsequent elevation of CPP and CBF<i>,</i> although this effect was significantly stronger and of longer duration after HTS.<br/> Another 2 RCTs reported a difference in the ratio of uncontrolled ICP between the 2 groups, and the definition of uncontrolled ICP in these 2 RCTs differed, as did the time frames for data collection. 1 of these RCTs found both interventions to be effective, but added pretreatment factors need to be considered (e.g. serum sodium and haemodynamics). The 5th RCT found HTS to be more effective for increased ICP than mannitol but cautioned the benefit in this trial might be explained by "local osmotic effects". </p> <p>2 RCTs in which intervention was only given after CSF drainage had failed, reported the mean fall in ICP following a dose averaged over hundreds of episodes across 4‐6 days of treatment. Of these 2 RCTs, 1 found HTS to be superior to mannitol; the other found no clear difference between groups. </p> <p><b>HTS vs mannitol vs mannitol plus glycerol</b> </p> <p>A 6th RCT comparing HTS with mannitol and also with mannitol plus glycerol reported means and ranges of change within an hour following a single dose. They reported all 3 hyperosmolar agents (HTS, mannitol and mannitol plus glycerol) as effective, but HTS was slightly superior, effecting a greater change in reducing ICP, and more quickly, than other agents, while at a lower dose. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> <p>(6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is not possible to pool these data because of variations in timings and ways of reporting ICP </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A rebound phenomenon</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>None of the RCTs reported on this outcome systematically, although it is mentioned in passing as potentially affecting those treated with mannitol in 1 RCT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was reported in just 1/4 RCTs available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary oedema</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute renal failure</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CPP:</b> cerebral perfusion pressure; <b>CSF:</b> cerebrospinal fluid; <b>HTS:</b> hypertonic saline; <b>ICP</b> : Intracranial pressure: <b>ICU:</b> intensive care unit; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TBI:</b> traumatic brain injury </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded for imprecision (low number of participants), risk of bias and indirectness (1 trial included a mixed population of whom only a third had TBI).<br/> <sup>b</sup>We downgraded for imprecision, inconsistency and risk of bias.<br/> <sup>c</sup>We downgraded for imprecision, indirectness and risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010904-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010904-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010904-sec-0140">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD010904-sec-0030"></div> <section id="CD010904-sec-0031"> <h3 class="title" id="CD010904-sec-0031">Description of the condition</h3> <p>Traumatic brain injury is a major cause of death and disability worldwide (<a href="./references#CD010904-bbs2-0043" title="CorriganJD , SelassieAW , OrmanJA . The epidemiology of traumatic brain injury. Journal of Head Trauma Rehabilitation2010;25(2):72. ">Corrigan 2010</a>). Intracranial hypertension secondary to traumatic brain injury is well known to have a profound influence on outcome, and severe intracranial hypertension has been associated with higher morbidity (<a href="./references#CD010904-bbs2-0065" title="MillerJD , BeckerDP , WardJD , SullivanHG , AdamsWE , RosnerMJ . Significance of intracranial hypertension in severe head injury. Journal of Neurosurgery1977;47(4):503‐16. ">Miller 1977</a>). Intracranial pressure is the pressure in the cranium, and the brain has a very limited ability to compensate for haemorrhage, swelling, oedema, or mass effects due to the invariant constraints of the cranial vault (<a href="./references#CD010904-bbs2-0078" title="StevensRD , HuffJS , DuckworthJ , PapangelouA , WeingartSD , Smith , WS . Emergency neurological life support: intracranial hypertension and herniation. Neurocritical Care2012;17(1):60‐5. ">Stevens 2012</a>). Intracranial pressure in the intact cranium is determined by the brain parenchyma tissue pressure, presence of mass lesions, cerebral blood volume, and intracranial cerebrospinal fluid volume (<a href="./references#CD010904-bbs2-0046" title="GreveMW , ZinkBJ . Pathophysiology of traumatic brain injury. Mount Sinai Journal of Medicine2009;76(2):97‐104. ">Greve 2009</a>). Intracranial hypertension is defined as a sustained (longer than five minutes) elevation of ICP above 20 mmHg (<a href="./references#CD010904-bbs2-0040" title="BrattonSL , ChestnutRM , GhajarJ , McConnellFH , HarrisOA , HartlR , et al. Guidelines for the management of severe traumatic brain injury. VIII. Intracranial pressure thresholds. Journal of Neurotrauma2007;24:S55‐8. ">Bratton 2007</a>). Sustained intracranial hypertension indicates life‐threatening neurological emergencies that require immediate recognition and treatment to prevent irreversible injury and death. In a review of trials of the value of intracranial pressure in predicting outcomes in traumatic brain injury, the risk of death was 18.4% for participants with intracranial pressure less than 20 mmHg and 24.8% for participants with intracranial pressure between 20 mmHg and 40 mmHg but 55.6% for those with intracranial pressure greater than 40 mmHg (<a href="./references#CD010904-bbs2-0080" title="TreggiariMM , SchutzN , YanezND , RomandJA . Role of intracranial pressure values and patterns in predicting outcome of traumatic brain injury: a systematic review. Neurocritical Care2007;6(2):104‐12. ">Treggiari 2007</a>). Achieving a sustained reduction in elevated intracranial pressure remains a focus of neurocritical care. </p> </section> <section id="CD010904-sec-0032"> <h3 class="title" id="CD010904-sec-0032">Description of the intervention</h3> <p>Currently available medical treatments for raised intracranial pressure include hyperosmolar therapy, sedation and paralysis, hyperventilation, barbiturates, hypothermia, steroids and surgical intervention (<a href="./references#CD010904-bbs2-0072" title="Rangel‐CastilloL , GopinathS , RobertsonCS . Management of intracranial hypertension. Neurologic Clinics2008;26(2):521‐41. ">Rangel‐Castillo 2008</a>). </p> <p>Hyperosmolar therapy is the cornerstone of pharmaceutical treatment for intracranial hypertension. The physiological basis of osmotherapy was first published by Weed and Mckibben (<a href="./references#CD010904-bbs2-0083" title="WeedLH , McKibbenPS . Experimental alteration of brain bulk. American Journal of Physiology‐Legacy Content1919;48(4):531‐58. ">Weed 1919</a>). Intravenous injection of a hypertonic solution was followed by a marked decrease in size of the brain. Since that time, mannitol, a sugar alcohol that acts as an osmotic diuretic, causing sustained hyperosmolarity by dehydration, has become the most widely used hyperosmolar solution to treat elevated intracranial pressure. Increasingly, hypertonic saline has emerged as an alternative hyperosmolar agent after several trials reported its relative superiority, especially for refractory intracranial pressure (<a href="./references#CD010904-bbs2-0051" title="HornP , MünchE , VajkoczyP , HerrmannP , QuintelM , SchillingL , et al. Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. Neurological Research1999;21(8):758‐64. ">Horn 1999</a>; <a href="./references#CD010904-bbs2-0057" title="KhannaS , DavisD , PetersonB , FisherB , TungH , O'QuigleyJ , et al. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in paediatric traumatic brain injury. Critical Care Medicine2000;28(4):1144‐51. ">Khanna 2000</a>; <a href="./references#CD010904-bbs2-0069" title="OddoM , LevineJM , FrangosS , CarreraE , Maloney‐WilenskyE , PascualJL , et al. Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension. Journal of Neurology, Neurosurgery, and Psychiatry2009;80:916‐20. ">Oddo 2009</a>). </p> <p>Hypertonic saline firstly gained attention as a potentially more effective alternative to normal saline in the initial resuscitation of haemorrhagic shock (<a href="./references#CD010904-bbs2-0048" title="GunnarWP , MerlottiGJ , BarrettJ , JonassonO . Resuscitation from hemorrhagic shock. Alterations of the intracranial pressure after normal saline, 3% saline and dextran‐40. Annals of Surgery1986;204:686‐92. ">Gunnar 1986</a>). A survival benefit was shown when used for patients with combined haemorrhagic shock with head injury. The favourable effect on survival was attributed to the hyperosmolar characteristics of hypertonic saline and the resultant reduction in intracranial pressure. Since then, more clinical trials have found that the intravenous bolus administration of hypertonic saline resulted in a sustained reduction of intracranial pressure on patients with traumatic cerebral oedema, even when elevated intracranial pressure is resistant to other intracranial pressure‐lowering agents including mannitol (<a href="./references#CD010904-bbs2-0085" title="ZiaiWC , ToungTJ , BhardwajA . Hypertonic saline: first‐line therapy for cerebral edema?. Journal of the Neurological Sciences2007;261(1‐2):157‐66. ">Ziai 2007</a>). </p> <p>Although treatment protocols for administering hypertonic saline vary (<a href="./references#CD010904-bbs2-0068" title="MortazaviMM , RomeoAK , DeepA , GriessenauerCJ , ShojaMM , TubbsRS , et al. Hypertonic saline for treating raised intracranial pressure: literature review with meta‐analysis. Journal of Neurosurgery2012;116(1):210‐21. ">Mortazavi 2012</a>), retrospective trials suggest a definite intracranial pressure reduction is observed with the use of hypertonic saline independent of the dosage, the concentration or the administration strategy (<a href="./references#CD010904-bbs2-0059" title="Lewandowski‐BelferJJ , PatelAV , DarracottRM , JacksonDA , NordeenJD , FreemanWD . % hypertonic saline for refractory intracranial hypertension. Neurocritical Care2014;20:436‐42. ">Lewandowski‐Belfer 2014</a>; <a href="./references#CD010904-bbs2-0062" title="MaguiganKL , DennisBM , HamblinSE , GuillamondeguiOD . Method of hypertonic saline administration: effects on osmolality in traumatic brain injury patients. Journal of Clinical Neuroscience2017;39:147‐50. ">Maguigan 2017</a>; <a href="./references#CD010904-bbs2-0075" title="RoquillyA , MahePJ , LatteDD , LoutrelO . Continuous controlled‐infusion of hypertonic saline solution in traumatic brain‐injured patients: a 9‐year retrospective study. Critical Care2011;15:R260. ">Roquilly 2011</a>). Reported concentration and volume of hypertonic saline for clinical use range from 2% to 23.4% in concentration and 10 to 30 mL/kg in volume (<a href="./references#CD010904-bbs2-0068" title="MortazaviMM , RomeoAK , DeepA , GriessenauerCJ , ShojaMM , TubbsRS , et al. Hypertonic saline for treating raised intracranial pressure: literature review with meta‐analysis. Journal of Neurosurgery2012;116(1):210‐21. ">Mortazavi 2012</a>). </p> </section> <section id="CD010904-sec-0033"> <h3 class="title" id="CD010904-sec-0033">How the intervention might work</h3> <p>The intracranial pressure‐lowering mechanisms of hypertonic saline solutions are believed to be due to their effects on microcirculation and osmotic action (<a href="./references#CD010904-bbs2-0085" title="ZiaiWC , ToungTJ , BhardwajA . Hypertonic saline: first‐line therapy for cerebral edema?. Journal of the Neurological Sciences2007;261(1‐2):157‐66. ">Ziai 2007</a>). Hypertonic saline solutions decrease serum viscosity and hematocrit, leading to an increase in cerebral perfusion and causing cerebral arteriole vasoconstriction that reduces cerebral blood volume and intracranial pressure. Water always flows from body compartments with low osmolality to those with higher osmolality. Hypertonic saline solutions increase plasma osmolality after administration, thus promoting gradual movement of water from tissues into the circulation. As fluid moves into the vascular space and is carried away by the blood, the brain shrinks and intracranial pressure is reduced. </p> </section> <section id="CD010904-sec-0034"> <h3 class="title" id="CD010904-sec-0034">Why it is important to do this review</h3> <p>Hyperosmolar therapy is standard practice in most neurosurgical centres worldwide (<a href="./references#CD010904-bbs2-0040" title="BrattonSL , ChestnutRM , GhajarJ , McConnellFH , HarrisOA , HartlR , et al. Guidelines for the management of severe traumatic brain injury. VIII. Intracranial pressure thresholds. Journal of Neurotrauma2007;24:S55‐8. ">Bratton 2007</a>). The recent consensus suggest the use of mannitol or hypertonic saline solutions for reducing increased intracranial pressure in neuro‐intensive care patients (<a href="./references#CD010904-bbs2-0070" title="OddoM , PooleD , HelbokR , MeyfroidtG , StocchettiN , BouzatP , et al. Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. Intensive Care Medicine2018;44(4):449‐63. ">Oddo 2018</a>). Guidelines for the management of severe pediatric brain traumatic injury recommend bolus hypertonic saline (3%) in patients with intracranial hypertension (<a href="./references#CD010904-bbs2-0058" title="KochanekPM , TaskerRC , CarneyN , TottenAM , AdelsonPD , SeldenNR , et al. Guidelines for the management of pediatric severe traumatic brain injury: update of the brain trauma foundation guidelines, executive summary. Neurosurgery2019;84:1169‐78. ">Kochanek 2019</a>). Intravenous infusion of mannitol has been considered by some to be the ‘gold standard’ for the treatment of increased intracranial pressure, mostly due to its long history (<a href="./references#CD010904-bbs2-0063" title="MarkoNF . Hypertonic saline, not mannitol, should be considered gold‐standard medical therapy for intracranial hypertension. Critical Care2012;16(1):113. ">Marko 2012</a>). Some clinical trials suggest that hypertonic saline solutions can reduce raised intracranial pressure (<a href="./references#CD010904-bbs2-0051" title="HornP , MünchE , VajkoczyP , HerrmannP , QuintelM , SchillingL , et al. Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. Neurological Research1999;21(8):758‐64. ">Horn 1999</a>; <a href="./references#CD010904-bbs2-0056" title="KerwinAJ , SchincoMA , TepasJJ3rd , RenfroWH , VitarboEA , MuehlbergerM . Hypertonic saline for the management of elevated intracranial pressure in patients with severe traumatic brain injury: a pilot study. Journal of Trauma2009;67(2):277‐82. ">Kerwin 2009</a>; <a href="./references#CD010904-bbs2-0057" title="KhannaS , DavisD , PetersonB , FisherB , TungH , O'QuigleyJ , et al. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in paediatric traumatic brain injury. Critical Care Medicine2000;28(4):1144‐51. ">Khanna 2000</a>; <a href="./references#CD010904-bbs2-0084" title="WorthleyLI , CooperDJ , JonesN . Treatment of resistant intracranial hypertension with hypertonic saline: report of two cases. Journal of Neurosurgery1988;68(3):478‐81. ">Worthley 1988</a>), but its use can still be controversial in the field of TBI. We undertook this review to enable better understanding of the comparative efficacy and safety of hypertonic saline versus other intracranial pressure‐lowering agents for people with acute traumatic brain injury. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010904-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010904-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010904-sec-0145">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010904-sec-0035"></div> <p>To assess the comparative efficacy and safety of hypertonic saline versus other intracranial pressure‐lowering agents in the management of acute traumatic brain injury. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010904-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010904-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010904-sec-0146">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010904-sec-0036"></div> <section id="CD010904-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010904-sec-0038"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) with a parallel design. We excluded cross‐over trials as incompatible with assessing long‐term outcomes. </p> </section> <section id="CD010904-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included participants of any age, with clinically defined traumatic brain injury of any severity, seen in the acute setting. </p> </section> <section id="CD010904-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Any hypertonic saline in any dosage for any duration, given at any time within eight weeks following injury. Hypertonic saline had to be compared with another intracranial pressure‐lowering agent, such as mannitol, barbiturates or steroids. </p> <p>We excluded any trials that used sodium lactate as an hypertonic saline, as, although it is a hyperosmolar solution, its effects cannot be attributed to a classical osmotic effect (<a href="./references#CD010904-bbs2-0013" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. IchaiC , ArmandoG , OrbanJ C , BerthierF , RamiL , Samat‐LongC , et al. Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain‐injured patients. Intensive Care Medicine2009;35:471‐9. ">Ichai 2009</a>; <a href="./references#CD010904-bbs2-0052" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. ">Ichai 2013</a>). Sodium lactate differs fundamentally from sodium chloride because lactate is a metabolisable anion; this means that even with comparable osmolarity in vitro, sodium lactate becomes two times less hypertonic than equiosmotic sodium chloride in the body. </p> </section> <section id="CD010904-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD010904-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010904-list-0001"> <li> <p>Death at final follow‐up (grouped by period of reporting e.g. short term (while in ICU); long term (at six months) </p> </li> </ul> </p> </section> <section id="CD010904-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010904-list-0002"> <li> <p>'Poor outcome' (death, persistent vegetative state or severe disability) at final follow‐up (as measured by the Glasgow Outcome Scale (GOS); <a href="./references#CD010904-bbs2-0054" title="JennettB , BondM . Assessment of outcome after severe brain damage: a practical scale. Lancet1975;305(7905):480‐4. ">Jennett 1975</a>; <a href="./references#CD010904-bbs2-0079" title="TeasdaleG , JennettB . Assessment of coma and impaired consciousness. A practical scale. Lancet1974;2(7872):81‐4. ">Teasdale 1974</a>). The GOS score, where possible, was converted into a dichotomous outcome. A 'poor outcome' is defined above; a ‘good outcome’ includes GOS categories of moderate disability or good recovery. </p> </li> <li> <p>Uncontrolled intracranial pressure during treatment (we define uncontrolled intracranial pressure as failure to decrease the intracranial pressure to target and/or requiring additional intervention; <a href="./references#CD010904-bbs2-0041" title="BurgessS , Anu‐LabanRB , SlavikRS , VuEN , ZedPJ . A systematic review of randomized controlled trials comparing hypertonic sodium solutions and mannitol for traumatic brain injury: implications for emergency department management. Annals of Pharmacotherapy2016;50(4):291‐300. ">Burgess 2016</a>). </p> </li> <li> <p>A 'rebound phenomenon' during treatment (we define rebound phenomenon as intracranial pressure rising above its original level after hyperosmolar therapy. Leakage of osmotic agent into the brain parenchyma through an altered blood brain barrier and secondary reversal of osmotic gradient with subsequent increase in brain oedema is considered the major cause of rebound). </p> </li> <li> <p>Pulmonary oedema during treatment.</p> </li> <li> <p>Acute renal failure during treatment.</p> </li> </ul> </p> <section id="CD010904-sec-0044"> <h6 class="title">Sample size calculation</h6> <p>At protocol stage, we judged that 474 people are required to have a 90% chance of detecting, at a significance level of 5%, a decrease in death from 27% in the control group to 15% in the experimental group (<a href="./references#CD010904-bbs2-0061" title="LuJ , MarmarouA , ChoiS , MaasA , MurrayG , SteyerbergEW , Impact and Abic Study Group. Mortality from traumatic brain injury. Acta Neurochirurgica. Supplementum2005;95:281‐5. ">Lu 2005</a>). </p> </section> </section> </section> </section> <section id="CD010904-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not restrict searches by date, language or publication status.</p> <section id="CD010904-sec-0046"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Injuries' Information Specialist ran searches in December 2019 (<a href="./appendices#CD010904-sec-0114">Appendix 1</a>); we also report earlier searches (<a href="./appendices#CD010904-sec-0120">Appendix 2</a>). The main amendment in the updated search in February 2017 was the inclusion of a more sensitive list of terms for hypertonic saline solution and hyperosmolar therapy. Searches were back‐dated to accommodate these changes. Additional searches were run in Chinese databases (see below) in August 2018. No relevant records resulted from the latter searches, and these were not re‐run in 2019. </p> <p>The Information Specialist ran searches on the following databases (all years):</p> <p> <ul id="CD010904-list-0003"> <li> <p>Cochrane Injuries' specialised register (11 December 2019);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 12) in the Cochrane Library; </p> </li> <li> <p>Ovid MEDLINE databases (1946 to 11 December 2019);</p> </li> <li> <p>Embase Classic + Embase (OvidSP) (1947 to 11 December 2019);</p> </li> <li> <p>ISI Web of Science: Science Citation Index‐Expanded (SCI‐EXPANDED) (1970 to 11 December 2019); </p> </li> <li> <p>ISI Web of Science: Conference Proceedings Citation Index‐Science (CPCI‐S) (1990 to 11 December 2019). </p> </li> </ul> </p> <p>Shuang Yang Liu, from the Department of Documentation and Retrieval, Xiangya Medical College, Central South University, searched the following Chinese databases in December 2013, November 2017 and September 2018: </p> <p> <ul id="CD010904-list-0004"> <li> <p>ChinaBiologyMedicinedisc (CBMdisc);</p> </li> <li> <p>Wanfang Data;</p> </li> <li> <p>China National Knowledge Infrastructure (CNKI);</p> </li> <li> <p>VIP Database for Chinese Technical Periodicals.</p> </li> </ul> </p> <p>The CBMdisc search strategy (<a href="./appendices#CD010904-sec-0126">Appendix 3</a>) was adapted as necessary for each of the other databases. </p> </section> <section id="CD010904-sec-0047"> <h4 class="title">Searching other resources</h4> <p>We also searched the following clinical trials registers (December 2019):</p> <p> <ul id="CD010904-list-0005"> <li> <p>Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> <p>We checked the reference lists of all identified relevant articles.</p> </section> </section> <section id="CD010904-sec-0048"> <h3 class="title" id="CD010904-sec-0048">Data collection and analysis</h3> <section id="CD010904-sec-0049"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HC and ZS) independently screened the search results and discussed the trials eligible for inclusion for searches run in 2013, examining each potential title. If titles were ambiguous, we read the abstracts. We resolved disagreement about inclusion of one trial (<a href="./references#CD010904-bbs2-0013" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. IchaiC , ArmandoG , OrbanJ C , BerthierF , RamiL , Samat‐LongC , et al. Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain‐injured patients. Intensive Care Medicine2009;35:471‐9. ">Ichai 2009</a>), by seeking the advice of the trial's correspondence author by email (<a href="./references#CD010904-bbs2-0052" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. ">Ichai 2013</a>), as the trial author informed us that they had used sodium lactate to decrease the raised intracranial pressure, and that sodium lactate differs fundamentally from sodium chloride because the absence of significant modification of plasma osmolality does not support a pure osmotic effect of sodium lactate, we excluded this trial. </p> <p>For the searches run after in 2017 and thereafter, JD assisted HC in screening the English language results. </p> </section> <section id="CD010904-sec-0050"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HC and ZS; HC and JD) independently extracted and recorded the data on specially designed forms and subsequently cross‐checked the data. We collected the following data from the trial reports: trial design, participant characteristics, intervention characteristics, outcome data, and adverse effects. Participant characteristics included age, sex and traumatic brain injury severity. Intervention characteristics included concentration, dosage, timing of administration and duration of intervention. Outcome measures included uncontrolled intracranial pressure (however defined by trial authors: our own definition was "failure to decrease the intracranial pressure to target and/or requiring additional intervention<i>"</i>, mortality and disability according to GOS score (<a href="./references#CD010904-bbs2-0054" title="JennettB , BondM . Assessment of outcome after severe brain damage: a practical scale. Lancet1975;305(7905):480‐4. ">Jennett 1975</a>; <a href="./references#CD010904-bbs2-0079" title="TeasdaleG , JennettB . Assessment of coma and impaired consciousness. A practical scale. Lancet1974;2(7872):81‐4. ">Teasdale 1974</a>), dichotomised in the standard way. We used <a href="./references#CD010904-bbs2-0073" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> software in the completion of this review. </p> </section> <section id="CD010904-sec-0051"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HC and JD) independently assessed the risk of bias for each included trial. We evaluated six domains: sequence generation, allocation concealment, blinding (subdivided into blinding of participants, treating physicians, and outcome assessors), incomplete outcome data, selective outcome reporting and other sources of bias. We judged the risk of bias in each category as high risk, low risk or unclear risk according to guidance on use of the risk of bias tool within <i>The Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010904-bbs2-0050" title="HigginsJP , AltmanDG , SterneJA , editors. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We approached the contact authors of all included trials to ask for clarification of trial methods and to request the trial protocols (where available). We intended to resolve any disagreements by consensus; however, no disagreements arose between review authors on the 'Risk of bias' judgements. </p> </section> <section id="CD010904-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we present results as summary risk ratios (RRs) with 95% confidence intervals (CIs). Additionally, as described above, we determined at the protocol development stage that we would transform the GOS score into a dichotomous outcome. 'Death or disability' would mean death, persistent vegetative state and severe disability; a 'good outcome' would include moderate disability and good recovery. </p> <p>Where trials presented other data as continuous data, such as 'uncontrolled intracranial pressure during treatment', we proposed to use mean differences (MDs) or standardised mean differences (SMDs), if data were measured in varying scales, with 95% CIs between the trial groups. </p> </section> <section id="CD010904-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>We did not include cross‐over RCTs in this review, although we identified several. For rapidly changing intracranial pressure, we determined at protocol stage that although feasible, cross‐over trials were not suitable for our review question, given that our primary outcome (death) was a long‐term one and that even in the short term, 'carry‐over' effects confound the estimates of the treatment effects in rapidly changing intracranial pressure. </p> <p>Our searches did not identify any cluster‐randomised trials. For the one trial included within this review with more than two eligible arms, data were unsuitable for pooling with those from other trials. Therefore, for this review, the unit of analysis is the individual participant. </p> </section> <section id="CD010904-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>As planned at protocol stage, we made every effort to contact trial authors to acquire missing data. We initially planned to prefer data reported according to intention‐to‐treat principles. As this was not possible in one key trial, we conducted best‐case and worst‐case analyses for the primary outcome (death at longest follow‐up) and also for GOS (in trials that provided data suitable for this purpose). </p> </section> <section id="CD010904-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned at protocol stage to use the Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD010904-bbs2-0049" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in metaanalyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), to assess statistical heterogeneity and we report these values, where relevant, in <a href="./full#CD010904-sec-0060">Results</a>. Heterogeneity in terms of treatment protocols, mode and timing of intervention delivery are described below, and discussed in relevant sections of the review (<a href="./references#CD010904-bbs2-0045" title="DeeksJJ , HigginsJP , Altman DG(editors) . Chapter 10: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook. ">Deeks 2019</a>). </p> </section> <section id="CD010904-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>In the future, if meta‐analysis is feasible and if more than 10 trials are available for the primary outcome, we plan to use a funnel plot to assess publication bias.<br/> <br/> In this version of the review, we compared the trial protocols or trial registrations (where available) with the published reports, to assess the likelihood of selective outcome reporting. </p> </section> <section id="CD010904-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We planned, if data were available for the same outcome measure in more than one trial, to attempt a meta‐analysis, analysing outcomes providing dichotomous data using the RR and 95% CI using a fixed‐effect model, conducting all analyses using Review Manager 5 (<a href="./references#CD010904-bbs2-0073" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We did not anticipate continuous outcomes at protocol stage, but henceforth plan to do so utilising MD where the same scales are used, and SMD where different trials report different scales, with 95% CI. </p> </section> <section id="CD010904-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to explore the effects by subsets of participants (children and adults) and by subsets of interventions (e.g. different dosage and different duration, with or without a colloid), but data were not sufficient for such analyses for the present version of the review. We will attempt these subgroup explorations in future versions of the review if and when there are sufficient data. </p> </section> <section id="CD010904-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis for allocation concealment (adequate vs 'unclear' or 'not done'), but there were not enough trials to enable us to do so. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010904-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010904-sec-0060"></div> <section id="CD010904-sec-0061"> <h3 class="title">Description of studies</h3> <p>See also: <a href="./references#CD010904-sec-0136" title="">Characteristics of included studies</a>; <a href="./references#CD010904-sec-0137" title="">Characteristics of excluded studies</a>. </p> <section id="CD010904-sec-0062"> <h4 class="title">Results of the search</h4> <p>Initial searches run in December 2013 identified 2841 records. After deduplication, 2488 potentially relevant search results remained, which we (HC and ZS) screened. We excluded 2478 of these records on the basis of their title or abstract. We examined the full text of the 10 remaining reports, and thus identified three trials that met the inclusion criteria, and seven were formally excluded. </p> <p>An update search (10 February 2017) retrieved 1249 new records<i>,</i> of which 740 proved to be internal duplicates or overlaps with previous searches, yielding 509 unique records. We identified and included one further eligible trial (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>), and assessed and excluded a further 11 reports. We ran 'top‐up' searches in August 2018 and in December 2019. The 2018 searches found 265 records, 204 records when deduplicated, which we screened. We did not include any eligible trials, but nine were formally excluded at full‐text stage. The 2019 searches identified 217 records, 180 when deduplicated. Of these, we identified and included two eligible trials (<a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), and formally excluded two trials. The trial identification process is outlined in <a href="#CD010904-fig-0001">Figure 1</a> (<a href="./references#CD010904-bbs2-0066" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). </p> <div class="figure" id="CD010904-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010904-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>We have identified one large trial as ongoing. In March 2019, we learned of a relevant RCT soon to commence in the UK, likely to report after 2023 (<a href="./references#CD010904-bbs2-0037" title="Salt or Sugar (SOS) trial: hyperosmolar in traumatic brain injury. Ongoing study 1 June 2019‐1 December 2023. ">Salt or Sugar 2019</a>), details of which can be found in <a href="./references#CD010904-sec-0139" title="">Characteristics of ongoing studies</a>; a record of this was identified in register searches later in the year. </p> </section> <section id="CD010904-sec-0063"> <h4 class="title">Included studies</h4> <section id="CD010904-sec-0064"> <h5 class="title">Design</h5> <p>All six included trials (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), were conducted as parallel, RCTs. Five involved two arms and one (<a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), three arms. </p> </section> <section id="CD010904-sec-0065"> <h5 class="title">Sample sizes</h5> <p>Sample sizes tended to be small, ranging from 20 (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>), to 120 (<a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>). Data from 287 participants overall are included within this review, but as described below, 9% of these participants did not have diagnoses of traumatic brain injury. At protocol stage, we had estimated that 474 people were required to have a 90% chance of detecting, as significant at the 5% level, a decrease in death from 27% in the control group to 15% in the experimental group (<a href="./references#CD010904-bbs2-0061" title="LuJ , MarmarouA , ChoiS , MaasA , MurrayG , SteyerbergEW , Impact and Abic Study Group. Mortality from traumatic brain injury. Acta Neurochirurgica. Supplementum2005;95:281‐5. ">Lu 2005</a>); this target was manifestly not met within this review. </p> <p>Only one trial ‐ the smallest included within the review (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>, n = 20), which did not collect data beyond 120 minutes of infusion, reported undertaking a power calculation, using the following assumptions: "The study population size for the trial was calculated assuming a 40% ± 15% ICP [intracranial pressure] in the HSS group and a 20% ± 15% ICP reduction in the mannitol group, according to previous studies ....Based on the formula for a normal distribution and assuming a two‐sided type I error of .05 and a power of .80, ten patients in each of the two groups were required" (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>, p 796)<i>.</i> </p> <p>No other trial reported undertaking a sample size calculation a priori, and all other trials (with the exception of <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), describe their small sizes as limitations. The authors of <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> (n = 38), and <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> (n = 30), both explicitly reported small trial size underneath the 'limitations' sections of their papers; likewise, investigators involved in <a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a> (n =47), comment that "although the number of included patients was significantly larger than the number of patients included in most other comparable studies, the figures remained smaller than what would be needed to draw definite conclusions, especially when differences observed between subgroups are analyzed" (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>, p. 210). Authors of <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a> (n =32) also mention "the small patient population of each group" as a limitation, especially in the context of the "heterogeneity in the underlying neurological illness" (p R530). </p> </section> <section id="CD010904-sec-0066"> <h5 class="title">Setting</h5> <p>All trials took place in ICUs, usually based within university hospitals. Three trials were conducted in India (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), one trial each in France (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>), and Germany (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>), whilst the sixth trial included participants from both France and Israel (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>). Trials were published between 2005 and 2019; the earliest recruitment period appears to have commenced in 2002 (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>), and the latest in 2015 (<a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>). </p> </section> <section id="CD010904-sec-0067"> <h5 class="title">Participants</h5> <p>Inclusion and exclusion criteria varied amongst trials. Two were restricted solely to participants with traumatic brain injury severe enough to require intracranial pressure monitoring (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>); a third (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>), required that they were stable patients (with or without traumatic brain injury) with sustained elevated intracranial pressure of 20 mm Hg for 10 minutes, not related to procedural pain (resulting in a participant group of whom 85% (17/20) had severe traumatic brain injury and the remainder of whom had suffered strokes). The fourth included trial required that participants have severe brain damage (Glasgow Coma Scale (GCS) &lt; 8) with cerebral oedema, resulting in a participant group of whom only 31% (10) had a diagnosis of traumatic brain injury (the remainder had subarachnoid haemorrhage (9); brain infarctions (7); intracerebral haemorrhage (4) or "other" (2) (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>)). The inclusion criteria for <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> were that participants be screened by CT "to eliminate the need for surgery, then included if they had a GCS ≤8, and had sustained elevated ICP of &gt;20 mm Hg for more than 5 minutes". The sole paediatric trial (<a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>), required that participants have severe traumatic brain injury, defined as a score of ≤8 on the Pediatric GCS, and present within 24 hours of trauma. </p> <p>The one trial that focused on children under 16 years (<a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>), did not report an overall mean for age, but provided ranges of ages. Participants were very young; 18 out of 30 were under five years of age, and one child was 22 months old. Within the trials largely focused on adults, minimum age criteria ranged from 15 (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>), to 16 (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>), to 18 years (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>); the mean ages of included participants varied from around 30 (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>) to 47 years (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>). In the four trials that reported on gender, male participants constituted the majority. </p> <p>In terms of severity, participants ranged from means of GCS scores on admission of 7 (SD 2) to 8 (SD 2) in the two groups within the <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a> trial (n = 20), to the most severely affected participants within the review, those within the <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> trial (n = 38; median GCS scores = 4 in the hypertonic saline group (range 4 to 5) and 5 in the mannitol group (range 4 to 6). Authors of the two 'mixed' trials, which did not focus on traumatic brain injury, did not report the source of traumatic brain injuries (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>); authors of the traumatic brain injury‐only trials (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), did. Where reported, road traffic accidents accounted for the majority of traumatic brain injuries, followed by falls, assaults and 'other'. Three trials explicitly categorised the nature of lesions, for example, extradural haematoma, subdural haematoma, contusions, intraventricular haemorrhage, diffuse axonal injury (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>). </p> </section> <section id="CD010904-sec-0068"> <h5 class="title">Interventions</h5> <section id="CD010904-sec-0069"> <h6 class="title">Initiation of therapy; mode of intracranial pressure assessment</h6> <p>All six trials provided a detailed treatment protocol showing the stages by which clinicians determined if hyperosmolar therapy was indicated. In one trial (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>), hyperosmolar therapy was initiated when intracranial pressure elevation was above 15 mmHg. In <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>, the sole pediatric trial, trial authors aimed at maintaining an intracranial pressure of below 15 mmHg in children between 1 and 10 years of age and 18 mmHg in children aged 11 to 16 years of age, and treatment was only administered if intracranial pressure remained persistently above the cut‐off value for more than five minutes, in spite of cerebrospinal fluid drainage. The four other included trials (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), initiated the trial medications if intracranial pressure exceeded the 20 mmHg threshold; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> stood out amongst the adult trials for initiating treatment only after cerebrospinal fluid drainage. </p> <p>It must be noted that methods of intracranial pressure assessment differed between trials. Two trials (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>; <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>), used a standard intraparenchymal intracranial pressure device (Codman Microsensor intracranial pressure Monitoring System; Codman &amp; Shurtleff Inc, Raynham, MA, USA); one used a subdural bolt (<a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), one trial did not state technology used (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>), two used an intraventricular device alongside an extraventricular device allowing cerebrospinal fluid drainage (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>). In these latter trials, the hyperosmolar treatment that is the subject of this review was only initiated if cerebrospinal fluid drainage failed to control intracranial pressure, compelling one set of trial authors to see hyperosmolar treatment in this context as a 'second‐tier' and not a first‐line therapy (<a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>). </p> </section> <section id="CD010904-sec-0070"> <h6 class="title">Concentrations, duration of therapy and comparators</h6> <p>Four trials compared equiosmolar doses of hypertonic saline to mannitol; a fifth, equiosmolar doses of hypertonic saline, mannitol and mannitol in combination with glycerol, the sixth trial featured hypertonic saline hydroxyethyl starch versus mannitol. Concentrations and durations of infusions varied and are presented, put in order of concentration of hypertonic saline, as follows: </p> <p> <ul id="CD010904-list-0006"> <li> <p>one trial (n = 120) compared 3% hypertonic saline with 20% mannitol and with mannitol 10% plus 10% glycerol combination; "infused via the central venous line at a defined infusion rate, that is, 6 mL/minute or 120 drops/minute (osmolarity of mannitol, mannitol plus glycerol combination, and 3% HTS [hypertonic saline] are almost the same, ie, 1100 mOsm/L, 1049 mOsmo/L, and 1027 mOsm/L, respectively). The infusion was stopped when ICP [intracranial pressure] was reduced to &lt;15 mm Hg, which was our treatment goal" (<a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>, e222). Assessment stopped after a single infusion; </p> </li> <li> <p>two trials (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> (n = 38); <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> (n = 30)) compared administration of either 3% saline or 20% mannitol in an equiosmolar dose infused as a bolus through a central venous catheter over five minutes. Both mannitol and hypertonic saline were administered as 2.5 mL/kg doses. Both trials dealt with multiple episodes of raised intracranial pressure over four to six days, following cerebrospinal fluid drainage as mentioned above; </p> <ul id="CD010904-list-0007"> <li> <p><a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> administered a maximum of three doses of the same drug if the first dose of the osmotic agent failed to decrease the intracranial pressure to below 20 mmHg; </p> </li> <li> <p><a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> administered a maximum of two doses if the agent failed to decrease the intracranial pressure to one of two targets based on the age of the child (15 mmHg or 18 mmHg); </p> </li> </ul> </li> <li> <p>one trial (n = 32) compared 7.2% hypertonic saline hydroxyethyl starch (200/0.5) 6% versus 15% mannitol, infused via the central venous line using an automated infusion system at a defined infusion rate (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>). The infusion was stopped when intracranial pressure was reduced to less than 15 mmHg, defined as the treatment goal. Multiple infusions were often required; assessment stopped after discharge from ICU. </p> </li> </ul> <ul id="CD010904-list-0008"> <li> <p>one trial (n = 20) compared a single infusion of 100 mL of 7.45% saline (osmolarity, 2548 mOsm/L; hypertonic saline group) versus 231 mL of 20% mannitol (osmolarity, 1100 mOsm/L; mannitol group) for 20 minutes of administration via the central venous catheter (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>). Assessment was performed during a study period of 120 minutes; </p> </li> <li> <p>one trial (n = 47) compared hypertonic saline 7.5% (2 mL/kg) versus mannitol 20% (4 mL/kg) delivered intravenously for 20 minutes (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>); and as long as intracranial pressure remained elevated and monitored, all participants had a daily evaluation during which a baseline assessment was followed by two additional tests performed at 30 and 120 minutes after administration of hypertonic saline or mannitol. </p> </li> </ul> </p> </section> </section> <section id="CD010904-sec-0071"> <h5 class="title">Outcomes</h5> <p>The length of follow‐up (from one hour post infusion, to six months) impacted on the range of outcomes chosen. Four of six trials assessed mortality; one at end of stay in ICU, one at discharge from hospital and two at six months. We cannot disaggregate mortality data from the overall neurological outcome (GOS categories) in two trials (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011;</a><a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>). </p> <p>All trials measured intracranial pressure, although in different ways and by different means. </p> <p>Neurological outcome, even when assessed by a single instrument (GOS) used within three of six trials, did not make comparison straightforward. At six months, two trials reported GOS results dichotomised in the traditional way, grouping death, persistent vegetative state and severe disability together as a 'poor' outcome (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>), a third trial dichotomised a poor outcome as death or persistent vegetative state, versus all other outcomes (<a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>). <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> was short term in nature and so measured only the GCS at baseline and one hour after a successful infusion. </p> <p>No trial appeared systematically to assess adverse effects.</p> <p>Each trial is described in more detail in the <a href="./references#CD010904-sec-0136" title="">Characteristics of included studies</a> table and a separate table listing data reported by each trial at baseline and within the trial is also supplied (<a href="#CD010904-tbl-0002">Table 1</a>). </p> <div class="table" id="CD010904-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data collected within studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline measures</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, source of injury)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, weight)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, weight)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, source and type of injury, duration from injury to hospital ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, source and type of injury, duration from injury to EVD insertion) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data apparently collected, but not reported. Source of injury</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data included: initial GCS score; CT scan studies analyzed using Marshall criteria considering presence of<br/> basal cisterns compression, midline shift &gt; 5mm, and lesions &gt; 25cm3 in volume. Lesions were categorized into two subgroups: diffuse<br/> and focal </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: GCS score; 'preserved cerebral autoregulation'; 'injury to studied treatment (time in days), diagnosis (not all participants had TBI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: initial GCS score; SAPS, 'basic illness', brain infarct or not) etc; "simplified acute physiology score" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: Initial GCS score; GCS score post‐resuscitation; median GCS score at inclusion to trial; Predominant lesion on CT scan </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: Post‐resuscitation GCS; motor score; Marshal CT grade; predominant lesion in CT scan </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline: GCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICP data collected during trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fall in ICP (mean and SD before infusion, after 30 min, after 120 min, comparisons made using repeated measures model of ANOVA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fall in ICP reported as percentage decline from baseline values (mean ± SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fall in ICP (mean and range before infusion, terminating infusion, after 10 min, 30 min, 60 min); percentage decline calculated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute values of ICP; response to individual boluses of agents (means and SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean reduction in ICP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimum and maximum ICP (mmHG) at 1 hr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICP responses also compared based on analysis of percentages of the baseline (instead of absolute values) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time course of ICP changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time required to reduce ICP below 20mm Hg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean duration of ICP monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum change in ICP in percentage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 1: hours of ICP &gt; 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of ICP fall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 h mean ICP monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose and time required to reduce ICP below 15mm Hg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numbers of ICP elevations during average monitoring duration of 3.7 to 3.8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 h mean ICP monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICP tracings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time required to achieve ICP &lt; 20 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean numbers of raised ICP episodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of time ICP was maintained at &lt; 20 mmHg in a given day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'Effective' doses/'ineffective' doses (as regards ICP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean number of doses per day; instances of refractory ICP (mean (SD)) (defined as persistently elevated ICP despite 3 consecutive doses) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other interventions recorded</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgical intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inotrope intervention/duration of inotrope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery for evacuation of EDH, depressed skull fracture or contusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbiturate intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ionotropes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSF drainage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSF drainage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other data measured in ICU</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Common measures</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebral metabolic rate of glucose (CMRGlc (mg/100 g/min))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolarity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluid balance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluid balance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hematocrit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hematocrit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hematocrit</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of CSF drained</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of CSF drained</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) duration of ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures unique to individual trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global CBF (mL/100 g/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preserved cerebral autoregulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVDO<sup>2</sup>, AVDGlc and AVDLct contents were calculated allowing the determination of CMRO<sup>2</sup>; CMRGlc and CMRLct </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum chloride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SpO<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood urea nitrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum creatinine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shear Rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood flow velocities/arterial blood pressure (systolic, mean and diastolic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brain tissue oxygen tension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urine output (vol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arterial PH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PaO<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of stay data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days on ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of ICU stay/ duration of overall hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of ICU stay/ duration of overall hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality/ neuro outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In ICU, GCS score following interruption of sedative drugs. Neurological outcome at 6 months: GOS as 'good recovery', 'moderate disability', 'severe disability', 'persistent vegetative state' and 'death' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality at the end of stay in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In‐hospital mortality plus GOS scores/mortality at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GOS scores at 6 months (unconventionally dichotomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GCS at one hour after one dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AVDGlc:</b> Arterial jugular differences for glucose; <b>AVDLct</b> : Arterial jugular differences for lactate; <b>AVDO</b><sup>2</sup>: Arterial jugular differences for oxygen; <b>CBF</b> : cerebral blood flow; <b>CMRGlc</b> : cerebral metabolic rate of glucose; <b>CMRLct</b> : cerebral metabolic rate of lactate; <b>CMRO<sup>2</sup> </b> : cerebral metabolic rate of oxygen; <b>CPP</b> : cerebral perfusion pressure; <b>CSF</b> : cerebrospinal fluid; <b>CVP</b> : central venous pressure; <b>CT</b> : computed tomography; <b>EVD</b> : extraventricular drain; <b>GCS</b> : Glasgow Coma Scale; <b>GOS</b> : Glasgow Outcomes Scale; <b>ICH</b> : intracranial hypertension;<b>ICP</b> : intracranial pressure; <b>ICU</b> : intensive care unit; <b>MAP</b> : mean arterial pressure; <b>NICU</b> : neuro‐intensive care unit; <b>PaCO<sup>2</sup> </b> : partial pressure of carbon dioxide in arterial blood; <b>PaO<sup>2</sup> </b> : partial pressure of oxygen in arterial blood; <b>SAPS</b> : simplified acute physiology score; <b>SD</b> : standard deviation; <b>SPO2</b> = peripheral oxygen saturation </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD010904-sec-0072"> <h4 class="title">Excluded studies</h4> <p>See also the <a href="./references#CD010904-sec-0137" title="">Characteristics of excluded studies</a> table. </p> <p>29 trials are formally excluded from this review.</p> <section id="CD010904-sec-0073"> <h5 class="title">Studies excluded for design features</h5> <p>We excluded 16 trials in total due to features of their design. We excluded five trials due to their cross‐over design (<a href="./references#CD010904-bbs2-0007" title="BattisonC , AndrewsPJ , GrahamC , PettyT . Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Critical Care Medicine2005;33:196‐202; discussion 257‐8. ">Battison 2005</a>; <a href="./references#CD010904-bbs2-0008" title="BourdeauxCP , BrownJM . Randomized controlled trial comparing the effect of 8.4% sodium bicarbonate and 5% sodium chloride on raised intracranial pressure after traumatic brain injury. Neurocritical Care2011;15:42‐5. ">Bourdeaux 2011</a>; <a href="./references#CD010904-bbs2-0011" title="HuangX , YangL . Comparison of 20% mannitol and 15% hypertonic saline in doses of similar osmotic burden for treatment of severe traumatic brain injury with intracranial hypertension. Journal of Southern Medical University2014;34(5):723‐6. ">Huang 2014</a>; <a href="./references#CD010904-bbs2-0026" title="PolushinLS , KrylovVV , SvistovDV , BelkinAA , PetrikovSS , ShchegolevAV , et al. Correction of intracranial hypertension syndrome using hyperosmolar solutions in patients with severe brain damage (multicenter randomized clinical study). Anesteziologiia I Reanimatologiia2009;5:4‐8. ">Polushin 2009</a>; <a href="./references#CD010904-bbs2-0028" title="SakellaridisN , PavlouE , KaratzasS , ChroniD , VlachosK , ChatzopoulosK , et al. Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries. Clinical article. Journal of Neurosurgery2011;114:545‐8. ">Sakellaridis 2011</a>). Searches of the Chinese literature identified 11 trials, which had to be excluded due to unreliable data or methods (incorrect 'T' values, questionable sequence generation), which we could not clarify through contact with trial authors (<a href="./references#CD010904-bbs2-0012" title="HuangGR , GuanYJ , ZhenXH . The effects of 7.5% hypertonic saline in the severe traumatic brain injury with hemorrhagic shock. Journal of Bethune Medical Science2015;13(14):435‐6. ">Huang 2015</a>; <a href="./references#CD010904-bbs2-0016" title="JinHH , JinY , MaoTM , ChenY . 3% hypertonic saline in the treatment of severe brain injuries. Zhejiang Journal of Traumatic Surgery (Chinese)2018;23(4):659‐60. ">Jin 2018</a>; <a href="./references#CD010904-bbs2-0017" title="LiDH , ZhaoXZ , LiHL , ZhangXB . Effect of hypertonic saline on intracranial pressure and cerebral edema in patients with severe craniocerebral injury. Journal of Preventive Medicine of Chinese People Liberation Army (Chinese)2018;36(3):357‐60. ">Li 2018</a>; <a href="./references#CD010904-bbs2-0018" title="LiangCY . Comparison of effects of 3% hypertonic saline and 20% mannitol in raised intracranial pressure. Clinical Medicine2013;33(4):70‐1. ">Liang 2013</a>; <a href="./references#CD010904-bbs2-0019" title="LiuQ , YangF . The application of hypertonic saline on the brain injuries. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine (Chinese)2018;18(2):114‐15. ">Liu 2018</a>; <a href="./references#CD010904-bbs2-0020" title="MeiLK , WangL , YuJB . Comparison of effects of hypertonic saline and mannitol in raised intracranial pressure. China Medical Engineering2016;24(7):126‐7. ">Mei 2016</a>; <a href="./references#CD010904-bbs2-0025" title="NiXW , ChenF . Comparison of 3% hypertonic saline and 20% mannitol in the treatment of severe brain injuries. Modern Practical Medicine (Chinese)2018;30(6):739‐41. ">Ni 2018</a>; <a href="./references#CD010904-bbs2-0029" title="ShuZ , XuY , ShenXM , QiuYF . Comparison of effects of 3% hypertonic saline and mannitol in raised intracranial pressure. Chinese Journal of Hemorheology2015;1:67‐68, 117. ">Shu 2015</a>; <a href="./references#CD010904-bbs2-0033" title="ZhangY . Comparison of effects of hypertonic saline and mannitol in raised intracranial pressure. Henan Medical Research2014;23(11):74‐5. ">Zhang 2014</a>; <a href="./references#CD010904-bbs2-0034" title="ZhangYB . Comparison of effects of 3% hypertonic saline and 20% mannitol in severe traumatic brain injury. Contemporary Medicine2015;21(1):66‐7. ">Zhang 2015</a>; <a href="./references#CD010904-bbs2-0035" title="ZhangRJ , WangXF , LuoWY , WeiYJ , ZhangHB , ChenBB , et al. Comparison of hypertonic saline and mannitol in the treatment of intracranial pressure. Chinese Journal of Neurosurgery (Chinese)2018;34(6):632. ">Zhang 2018</a>). </p> </section> <section id="CD010904-sec-0074"> <h5 class="title">Termination</h5> <p>We excluded four registered trials because they were terminated, largely due to difficulties in recruitment (<a href="./references#CD010904-bbs2-0021" title="NCT01028339 (Direction Centrale du Service de Santé desArmées) . Mannitol vs HS to treat ICHT after severe TBI : comparison on PtiO2 and microdialysis values. clinicaltrials.gov/show/NCT01028339 (accessed 1 December 2017). ">NCT01028339</a>; <a href="./references#CD010904-bbs2-0022" title="NCT01108744 . Double blind study of hypertonic saline vs mannitol in the management of increased intracranial pressure (ICP). clinicaltrials.gov/show/NCT01108744 (accessed 1 December 2017). ">NCT01108744</a>; <a href="./references#CD010904-bbs2-0023" title="NCT01111682 (University of Cinncinati / US Dept of Defense). Hypertonic saline vs. mannitol for elevated intercranial pressure. clinicaltrials.gov/show/NCT01111682 (accessed 1 December 2017). ">NCT01111682</a>; <a href="./references#CD010904-bbs2-0024" title="NCT01215019 (Indiana University). Osmotic therapy for treatment of intracranial hypertension for traumatic brain injury. clinicaltrials.gov/ct2/show/NCT01215019 (accessed 1 December 2017). ">NCT01215019</a>. </p> </section> <section id="CD010904-sec-0075"> <h5 class="title">Miscellaneous (chiefly ineligible intervention or comparator)</h5> <p>We excluded nine trials for other reasons. We excluded two trials (<a href="./references#CD010904-bbs2-0015" title="JiangZ , XuH , WangM , LiZ , SuX , LiX , et al. Effect of infusion speed of 7.5% hypertonic saline on brain edema in patients with craniocerebral injury: an experimental study. Gene2018;665:201‐7. [DOI: 10.1016/j.gene.2018.05.005] ">Jiang 2018</a>; <a href="./references#CD010904-bbs2-0032" title="YangX , ChenY , LiJ , ChenL , RenH , LiuY , et al. Hypertonic saline maintains coagulofibrinolytic homeostasis following moderate‐to‐severe traumatic brain injury by regulating monocyte phenotype via expression of lncRNAs. Molecular Medicine Reports2019;19(2):1083‐91. ">Yang 2019</a>), because they compared differing doses of hypertonic saline, with no eligible control; one trial (<a href="./references#CD010904-bbs2-0014" title="JafariM , AlaS , HaddadiK , AlipourA , MojtahedzadehM , EhteshamiS , et al. Cotreatment with furosemide and hypertonic saline decreases serum neutrophil gelatinase‐associated lipocalin (NGAL) and serum creatinine concentrations in traumatic brain injury: a randomized, single‐blind clinical trial. Iranian Journal of Pharmaceutical Research : IJPR2018;17(3):1130‐40. ">Jafari 2018</a>), because they administered hypertonic saline to both groups, with furesimide as an added treatment; and one trial (<a href="./references#CD010904-bbs2-0009" title="DuDY , SunLT , ZhangWS , LiK , XuC , LiZF . The clinical efficacy of hypertonic saline in reducing intracranial pressure inpatients with severe traumatic brain injury. Neural Injury and Functional Reconstruction2017;12:215–17. ">Du 2017</a>) because there was no defined trigger for starting hyperosmotherapy to reduce ICP, and in addition, mannitol was administrated Q8h (every 8 hours). Following email communication with the trial author (<a href="./references#CD010904-bbs2-0052" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. ">Ichai 2013</a>), we excluded <a href="./references#CD010904-bbs2-0013" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. IchaiC , ArmandoG , OrbanJ C , BerthierF , RamiL , Samat‐LongC , et al. Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain‐injured patients. Intensive Care Medicine2009;35:471‐9. ">Ichai 2009</a> because they used sodium lactate with the aim of decreasing the raised intracranial pressure; although sodium lactate is a hyperosmolar solution, its effects cannot be attributed to a classical osmotic effect. It differs fundamentally from sodium chloride because lactate is a metabolisable anion; this means that even with comparable osmolarity in vitro, sodium lactate becomes two times less hypertonic than equiosmotic sodium chloride in the body. We excluded one trial (<a href="./references#CD010904-bbs2-0010" title="HongDQ , WuXX , HuY . The change of intracranial pressure and NSE after hypertonic saline in the treatment of severe brain injuries. Modern Doctor of China (Chinese)2017;55(36):15‐18. ">Hong 2017</a>), because of ineligible population. They administered hypertonic saline but not as a result of intracranial pressure monitoring. One trial appeared to meet the inclusion criteria, but was a nontherapeutic investigation that only considered coagulation (<a href="./references#CD010904-bbs2-0031" title="WangHF , CaoHS , ZhangXH , GeL , BieL . The effect of hypertonic saline and mannitol on coagulation in moderate traumatic brain injury patients. American Journal of Emergency Medicine2017;35:1404‐7. ">Wang 2017</a>). We excluded one trial (<a href="./references#CD010904-bbs2-0030" title="UpadhyayP , TripathiVN , SinghRP , SachanD . Role of hypertonic saline and mannitol in the management of raised intracranial pressure in children: a randomized comparative study. Journal of Pediatric Neurosciences2010;5:18‐21. ">Upadhyay 2010</a>), for multiple reasons: quasi‐randomisation; too low a proportion of participants with traumatic brain injury (only 7% traumatic brain injury). We excluded one ongoing trial (<a href="./references#CD010904-bbs2-0027" title="RoquillyA , AsehnouneK . Continuous hyperosomolar therapy for traumatic brain‐injured patients (COBI). clinicaltrials.gov/ct2/show/NCT031437512017. ">Roquilly 2017</a>), because its comparator, 'standard care', is unlikely to include alternative intracranial pressure‐lowering agents. </p> <p>One trial (<a href="./references#CD010904-bbs2-0036" title="VialetR , AlbaneseJ , ThomachotL , AntoniniF , BourgouinA , AlliezB , et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Critical Care Medicine2003;31:1683‐7. ">Vialet 2003</a>). awaits classification (see also <a href="./references#CD010904-sec-0138" title="">Characteristics of studies awaiting classification</a>) due to unreconciled discrepancies in numbers of participants reported within the paper. </p> </section> </section> </section> <section id="CD010904-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>Two figures show our assessment of the risk of bias of the included trials (<a href="#CD010904-fig-0002">Figure 2</a>; <a href="#CD010904-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD010904-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Six trials are included in this review" data-id="CD010904-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Six trials are included in this review </p> </div> </div> </div> <div class="figure" id="CD010904-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD010904-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD010904-sec-0077"> <h4 class="title">Allocation</h4> <section id="CD010904-sec-0078"> <h5 class="title">Random sequence generation</h5> <p>All included trials reported acceptable methods of generating randomisation sequence (either computer‐generated random‐number tables, or sealed, opaque envelopes) and so we judged them to be at low risk of bias. </p> </section> <section id="CD010904-sec-0079"> <h5 class="title">Allocation concealment</h5> <p>Three trials (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), concealed allocation by using sealed and opaque envelopes and we judged them to be at low risk of bias. <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a> and <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> did not describe the method of allocation concealment, and the assessment for both is thus 'unclear'. The trial author of <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> told us in a personal communication that, "we did not do allocation concealment", and so we judged it to be at high risk of bias. </p> </section> </section> <section id="CD010904-sec-0080"> <h4 class="title">Blinding</h4> <section id="CD010904-sec-0081"> <h5 class="title">Participants</h5> <p>We judged all the trials to have a low overall risk of bias for blinding of participants; all of the people recruited to the trials had a brain injury severe enough to have a GCS score of 8 or lower, were sedated, and so were unaware of the treatment they were receiving. </p> </section> <section id="CD010904-sec-0082"> <h5 class="title">Treating physicians</h5> <p>Overall, we judged the included trials to have a high risk of bias for blinding treating physicians. In <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>, it was not possible to blind administration because the two treatments were of different volumes. <a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a> explained in 2015 through correspondence that the team was well aware of the regimen at the acute phase. <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>, <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>, <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> and <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> did not describe blinding and it is unlikely to have been ensured. </p> </section> <section id="CD010904-sec-0083"> <h5 class="title">Outcome assessors</h5> <p>We judged trials to have varying risk of bias in blinding outcome assessors. <a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a> told us in a personal communication that, "as for the outcome, it was assessed in both centers by blinded medical staff during follow‐up visits or by phone calls issued by blinded personnel". <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> reported using an assessor unaware of treatment status. In <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>, <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a> and <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>, objective outcomes such as laboratory measures or death are unlikely to have been affected by problems of blinding. We judged the above trials at low risk of bias for blinding outcome assessors. We judged risk of bias for blinding outcome assessors in <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> as high risk, as they do not mention blinding and all outcomes were assessed in the short‐term. </p> </section> </section> <section id="CD010904-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>Complete outcome data were available for <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a> (n = 20) and for <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> (n = 30), two trials that followed participants up for a maximum of two hours post treatment. We therefore assessed these trials as being at low risk of bias for this domain. In <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>, data from eight out of 40 (20%) of the participants initially recruited were missing, but these participants were withdrawn from analysis before initiation of treatment, as their intracranial pressure never exceeded the treatment threshold of 20 mmHg. <a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a> excluded nine out of 56 randomised participants early, either because of intracranial pressure lower than 15 mmHg (n = 7) or serum osmolarity greater than 320 mOsm/L on admission (n = 2). Data for the remaining participants were complete. As we consider the data of participants who never reached treatment threshold to be missing completely at random, we also judged these trials to be at low risk of bias. The paediatric trial <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> reported that they assessed data on an intention‐to‐treat basis and these appear to be complete (all 30 participants analysed at all time points), so we judged this trial to be at low risk of bias for this domain. </p> <p>In the sixth included trial (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>), no data were missing at the point where 22 surviving participants were discharged from hospital, but we were confronted with the problem of missing data for four participants in each group at the time of six‐month follow‐up. Personal communication with trial authors confirmed that contact could not be maintained with participants or their carers by telephone (<a href="./references#CD010904-bbs2-0053" title="JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline[personal communication]. Email to: J Dennis 27 December 2017. ">Jagannatha 2017</a>). Data were insufficient to impute and we confined ourselves to using available data, conducting a best‐case and worst‐case scenario analysis, and commenting on the high risk of bias introduced by 35% loss to follow‐up for surviving participants leaving hospital. Given that this affects our assessment of the primary outcome for a large proportion of the sample of this trial, we therefore assess the risk of bias for this domain to be 'high'. </p> </section> <section id="CD010904-sec-0085"> <h4 class="title">Selective reporting</h4> <p>In correspondence with the trial authors during 2014, <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a> sent us a trial protocol (<a href="./references#CD010904-bbs2-0071" title="PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct]. Unpublished document [sent to HC by Dr J‐F Payen]2002 (May). ">Payen 2002</a>): a comparison with the completed trial revealed no suggestion of reporting bias; our assessment for bias is therefore 'low'. The assessment for all other trials is 'unclear' as either we could not identify any registration or protocol (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>), or trials were retrospectively registered (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>). </p> </section> <section id="CD010904-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <p> <ul id="CD010904-list-0009"> <li> <p>Two of the trials included within this review did not restrict recruitment to participants with traumatic brain injury (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>), meaning that only 91% of included data come from participants meeting all our inclusion criteria. </p> </li> <li> <p>In addition, as mentioned, trials within this review are small, which means that it is not surprising that half report important differences between groups at baseline. </p> <ul id="CD010904-list-0010"> <li> <p>Authors of the second largest trial (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>, n = 47), note that, "Although there was a statistical trend suggestive of a better outcome in patients in the MTL [mannitol] group, similar differences found in the cerebral metabolic rate of oxygen (CMRO2) values and GCS scores on admission between the two groups probably indicated some asymmetry in the degree of severity of injury and accounted for this neurological outcome difference (Fig. 5; <i>x</i><sup>2</sup> p = 0.0662)" (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>, p 2007). </p> </li> <li> <p>Potential bias may have run in the other direction in a second trial, as trial authors noted here: "The occurrence of twice the number of subdural hematomas in the mannitol group (15 versus seven) may have introduced a bias. Subdural hematomas by virtue of being a pathologically more severe form of injury may have necessitated a higher number of hyperosmolar boluses in the mannitol group" (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>, p 73). </p> </li> <li> <p>Authors of a third trial report "the clinical values in both groups were not normally distributed [at baseline]" (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>, p R532). </p> </li> <li> <p>Authors of <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> also note that some "[other] methodological issues need to be taken into account when interpreting our results. ... Though we intended to recruit consecutive patients, some patients were excluded for logistic reasons. The GCS at inclusion of the patient into the trial was much lower in this trial compared with other trials, with a median of 5 and 4 (eye opening and motor scores) in the mannitol and HTS groups, indicating a more severe injury. Some of the patients in the trial underwent surgery, which might have conferred some benefit in terms of ICP [intracranial pressure] reduction. The patients were controlled for GCS at the time of inclusion and not the type of lesion on CT scan. .... The groups, however, were comparable with respect to the overall radiological profile and findings at surgery. Also, to our surprise, even in the operated patients, the initial reduction of ICP was followed by a progressive increase over time. Poor glycaemic control in the mannitol group may also have influenced the outcome in these patients. The number of patients in the trial was small and this limited our outcome analysis" (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>) p 73. </p> </li> </ul> </li> </ul> <ul id="CD010904-list-0011"> <li> <p>Authors of <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> wrote that hyperosmolar therapy was effectively "used as a second tier treatment" ‐ only after failure of an extraventricular drain in promoting cerebrospinal fluid drainage to reduce intracranial pressure. They wrote that, "EVD [extraventricular drain] as an initial treatment may dilute the effect of hyperosmolar therapy. It is not known, whether there will be any difference in intracranial pressure reduction between mannitol and hypertonic saline if any of these agents are administered as first‐line therapy. Many centers do not use EVD for ICP [intracranial pressure] monitoring. When ICP monitoring is done using parenchymal sensor, option of CSF [cerebrospinal fluid] drainage is not available, and true effect of hyperosmolar therapy can be assessed". Related to this, different trials measured intracranial pressure in different ways: <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> listed the use of a subdural bolt, and they cited their failure to assess the advantages or disadvantages of the intracranial pressure‐measuring technique as a limitation. </p> </li> </ul> </p> </section> </section> <section id="CD010904-sec-0087"> <h3 class="title" id="CD010904-sec-0087">Effects of interventions</h3> <p>See: <a href="./full#CD010904-tbl-0001"><b>Summary of findings for the main comparison</b> Hypertonic saline compared with other intracranial pressure‐lowering agents for acute traumatic brain injury</a> </p> <p>All included trials compared hypertonic saline with mannitol, or mannitol in combination with glycerol, for the control of intracranial pressure. </p> <section id="CD010904-sec-0088"> <h4 class="title">Primary outcome</h4> <section id="CD010904-sec-0089"> <h5 class="title">Mortality</h5> <p>Three out of six included trials reported on our primary outcome (mortality); timings varied and meta‐analysis was feasible between only two trials. </p> <section id="CD010904-sec-0090"> <h6 class="title">Mortality (short‐term) prior to discharge from hospital</h6> <p><a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> (n = 38) reported that there were four deaths within the first six days of treatment, but did not specify in which group the deaths occurred. Personal contact established that during this period, three out of 18 participants in the hypertonic saline group and one out of 20 in the mannitol group died. The same trial further reported data on deaths after six days, but before participants left hospital, recording no further deaths in the hypertonic saline group but a further nine in the mannitol group. At this time point, there is a slight trend favouring hypertonic saline compared to mannitol (RR 3.33, 95% CI 0.38 to 29.25). </p> <p>Investigators within <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a> (n = 32), reported that seven of 17 (41.2%) people in the hypertonic saline group and nine of 15 (60%) people in the mannitol group died by the end of stay in the ICU. Within this small trial with a mixed population of whom only a third had traumatic brain injury, hypertonic saline did not reduce all‐cause mortality (RR 0.69, 95% CI 0.34 to 1.39). </p> </section> <section id="CD010904-sec-0091"> <h6 class="title">Mortality at six months</h6> <p>We pooled data from two trials (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>), for this outcome, but given the high loss to follow‐up in <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> (8 of 22 participants who survived to leave hospital could not be contacted at six months), we have chosen to present the data three ways (per protocol, 'worst‐case' scenario for hypertonic saline and 'best‐case' scenario for hypertonic saline; <a href="#CD010904-fig-0004">Figure 4</a>). Here we have considered the effects of all four missing participants from either group alternately surviving or dying. Available data results are as follows. Per protocol RR 0.84 (95% CI 0.46 to 1.55; I<sup>2</sup> = 0%; 2 trials, 85 participants). 'Worst‐case' and 'best‐case' scenarios suggest the following (extreme) potential parameters of effect: worst‐case RR 1.12 (95% CI 0.66 to 1.89; I<sup>2</sup> = 0%; 2 trials, 85 participants); best‐case RR 0.67 (95% CI 0.38 to 1.18; I<sup>2</sup> = 50%; 2 trials, 85 participants). None of these analyses show a difference between treatments. </p> <div class="figure" id="CD010904-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1. Hypertonic saline vs mannitol, outcome: 1.2 mortality: 6 months" data-id="CD010904-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1. Hypertonic saline vs mannitol, outcome: 1.2 mortality: 6 months </p> </div> </div> </div> </section> </section> </section> <section id="CD010904-sec-0092"> <h4 class="title">Secondary outcome</h4> <section id="CD010904-sec-0093"> <h5 class="title">Poor outcome (measured by the dichotomised Glasgow Outcome Scale)</h5> <p>At protocol stage, we planned to report this outcome in the conventional manner, that is, by converting GOS scores into a dichotomous outcome where ‘death or disability’ signifies death, persistent vegetative state and severe disability; and a ‘good outcome’ includes moderate disability and good recovery. Two trials reported data suitable for pooling for this outcome at six months (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>), although the uncertainty due to missing data from <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> referred to above remains a concern. We thus reported findings in a similar way (available data, 'best‐case' and 'worst‐case'). </p> <p>Within <a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>: 17 of 22 (77.3%) people in the hypertonic saline group and 14 of 25 (56%) people in the mannitol group died or had a severe disability at the end of the follow‐up period. In <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>, trial authors report that, "GOS scores at 6 months, dichotomized as unfavourable (GOS 1–3) and favorable (GOS 4–5)" are regarded as "comparable (p = 0.21)" (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>, p. 71). Twelve of 18 (67%) people in the hypertonic saline group and 16 of 20 (80%) people in the mannitol group died or had a severe disability at six months. These findings are difficult to interpret in the light of the missing data on mortality referred to above. Pooling produces a result in which we have low confidence due to missing data as well as acknowledged baseline imbalance in <a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a> (RR 1.09, 95% CI 0.82 to 1.44; I<sup>2</sup> = 67%; 2 trials, 85 participants; <a href="./references#CD010904-fig-0008" title="">Analysis 1.3</a>). We have also presented best‐ and worst‐case scenarios in <a href="#CD010904-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD010904-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Hypertonic saline versus mannitol, outcome: 1.3 GOS: poor outcome at 6 months (conventional dichotomisation)." data-id="CD010904-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypertonic saline versus mannitol, outcome: 1.3 GOS: poor outcome at 6 months (conventional dichotomisation). </p> </div> </div> </div> <p><a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> included solely children aged under 16 years. They also reported GOS, but dichotomised differently, grouping all children who survived (regardless of severity of disability) against those who died or remained in a persistent vegetative state. We could not, therefore, pool findings with those above. Results suggest no clear difference between groups (RR 0.72, 95% CI 0.14 to 3.61; 1 trial, 25 participants; <a href="./references#CD010904-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD010904-sec-0094"> <h5 class="title">Uncontrolled intracranial pressure</h5> <p>Only two trials (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>) reported ‘uncontrolled ICP’ and they each had a different definition of ‘uncontrolled ICP’. In addition, the unit of analysis of <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a> is 'episodes', while <a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a> is 'participants', so we could not incorporate them in a meta‐analysis. </p> <p>All six trials reported the effect of HTS or mannitol on ICP. Three trials (<a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>; <a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>; <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>) reported the mean magnitude of ICP reduction, with standard deviations. The other three trials (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>; <a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>; <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>) reported the initial ICP prior to, and immediately following, the administration by infusion of the study medication , in the form of means and ranges. We could not pool data for this outcome due to manifest heterogeneity in timings and modes of assessment, and other issues (including non‐normally distributed data, differing populations (adults and children, non‐TBI participants)). Therefore, we report results for this outcome narratively. </p> <p><a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>: absolute ICP measurement values were reported as 12.2 ± 6.1 mmHg and 13.9 ± 7.8 mmHg in the hypertonic saline group versus 10.5 ± 6.8 mmHg and 13.6 ± 7.5 mmHg in the mannitol group after 30 minutes and 120 minutes of the infusion, respectively. The mean magnitude of intracranial pressure reduction after 30 minutes and 120 minutes of the infusion in the hypertonic saline groups were 1.70 mmHg higher (1.99 lower to 5.39 higher) and 0.30 mmHg higher (4.09 lower to 4.69 higher), respectively. Trial authors reported that, "both HTS [hypertonic saline] and MTL [mannitol] effectively and equally reduced ICP [intracranial pressure] levels with subsequent elevation of CPP [cerebral perfusion pressure] and CBF [cerebral blood flow], although this effect was significantly stronger and of longer duration after HTS ... Further, effect of HTS on ICP appeared to be more robust in patients with diffuse brain injury" (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>, p 2003). </p> <p><a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a>: intracranial pressure was reported as being reduced by 45% ± 19% of baseline values (‐14 ± 8 mmHg) and by 32% ± 12% of baseline values (‐10 ± 4 mmHg ) in the mannitol group versus 35% ± 14% (‐10 ± 5 mmHg) and by 23% ±10% (‐6 ± 3 mmHg) in the HTS group at 60 minutes and at 120 minutes after the start of the study medication infusion, respectively). Only one person from the hypertonic saline group was a low responder to osmotherapy (with a reduction in intracranial pressure of &lt; 20% of baseline values at 60 minutes after the start of infusion). Trial authors found both interventions to be effective for this outcome but added pretreatment factors need to be considered (e.g. serum sodium and haemodynamics). </p> <p><a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>: a total of 53 episodes of raised intracranial pressure exceeding 20 mmHg from 15 people in the mannitol group required infusion of trial medication. For four of these episodes (7.5%), intracranial pressure was uncontrolled within an average of 8.7 (4.2 to 19.9) minutes. 57 episodes of increased intracranial pressure occurred in the 17 people in the hypertonic saline group. For two of these episodes (3.5%), intracranial pressure was uncontrolled within 6.0 (1.2 to 15.0) minutes. Trial authors in this trial concluded hypertonic saline to be more effective for increased intracranial pressure than mannitol but cautioned that the benefit in this trial might be explained by "local osmotic effects" as there had been no differences in baseline haemodynamics. </p> <p><a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>: trial authors here report that mean fall in intracranial pressure following a dose of hyperosmolar agent was 8.9 ± 8.4 mmHg in the mannitol group and 10.1 ± 8.7 mmHg in the hypertonic saline group, based on a comparison of 488 episodes of raised intracranial pressure across six days. The mean fall in intracranial pressure following a dose of hyperosmolar agent in the hypertonic saline group was 1.20 mmHg higher (‐0.37 lower to 2.77 higher) than with mannitol. Trial authors reported that this was significant and also that the percentage time for which intracranial pressure remained below a threshold of 20 mmHg on day 6 was significantly higher for hypertonic saline than mannitol. They also reported that cerebrospinal fluid drainage was performed on 41 ± 38 occasions in the mannitol group and 45 ± 31 occasions in the HTS group (p= 0.73). </p> <p><a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>: trial authors report that most episodes of raised intracranial pressure were first managed by cerebrospinal fluid drainage which was effective in "almost more than two thirds of episodes". Thereafter, if not managed and requiring administration of a hyperosmolar agent, the mean (SD) reduction in intracranial pressure was −5.67 (SD 3.9) in the hypertonic saline group; − 7.13 (SD 2.9) in the mannitol group (<a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a>, p 1003). Trial authors report that the difference was not statistically different. </p> <p><a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>: all findings in this trial relate to a single episode of raised intracranial pressure, after which assessment was carried on for a maximum of one hour (assessments were made at 10, 30 and 60 minutes). Investigators reported data in the form of means and ranges (rather than standard deviations); they then report findings in percentage improvements. All three hyperosmolar agents (hypertonic saline, mannitol and mannitol plus glycerol) were reported as effective, but hypertonic saline was slightly superior, effecting a greater change in reducing intracranial pressure, and more quickly, than other agents, while at a lower dose. The "maximum change in ICP [intracranial pressure] occurred after the bolus dose of 3% HTS [hypertonic saline]"; the "maximum decrease in ICP was produced by 3% HTS (60%), followed by the 10% mannitol plus 10% glycerol combination group (57%) and then 20% mannitol (55%). When the 3 groups were compared, 3% HTS required the lowest dose, that is, 1.4 mL/kg, followed by the 10% mannitol plus 10% glycerol combination group, that is, 1.7 mL/kg, and then the 20% mannitol group, that is, 2 mL/kg." The time required to reduce intracranial pressure below 15 mm Hg was 16 minutes (range 6 to 39 minutes) in the 3% hypertonic saline group, 23 minutes in the mannitol group (range, 10 to 70 minutes) and 19 minutes in the 10% mannitol plus 10% glycerol combination group (range, 7 to 50) minutes. </p> </section> <section id="CD010904-sec-0095"> <h5 class="title">A rebound phenomenon during treatment</h5> <p>None of the trials reported on this outcome systematically, although it is mentioned in passing as potentially affecting those treated with mannitol in one trial (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>). </p> </section> <section id="CD010904-sec-0096"> <h5 class="title">Pulmonary oedema during treatment</h5> <p>None of the trials reported data on pulmonary oedema during treatment.</p> </section> <section id="CD010904-sec-0097"> <h5 class="title">Acute renal failure during treatment</h5> <p>None of the trials reported data on acute renal failure during treatment.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010904-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010904-sec-0098">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010904-sec-0170">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010904-sec-0098"></div> <section id="CD010904-sec-0099"> <h3 class="title" id="CD010904-sec-0099">Summary of main results</h3> <p>There are six trials, involving a total of 287 people, included in this review. We assessed the overall risk of bias in most trials as unclear or high, due either to mixed population or other factors, such as the impact of incomplete outcome data. </p> <p>Some pooling of data was possible for the primary outcome (mortality), as well as for the outcome of 'poor outcome' as assessed by traditional dichotomisation of GOS. We report other results narratively. Our certainty in all results is very low. Not enough people have been randomised into eligible trials to be able to give a reliable result. </p> <section id="CD010904-sec-0100"> <h4 class="title">Mortality</h4> <p>Two trials reported mortality in the short term, prior to discharge from hospital. One (n = 38) reported that three out of 18 participants in the hypertonic saline group and one out of 20 participants in the mannitol group died in the first six days following treatment, after which no further deaths occurred in the hypertonic saline group but a further nine deaths occurred in the comparator group (mannitol) prior to discharge (<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>). At this time point, there is no clear difference between groups (RR 0.33, 95% CI, 0.11 to 1.02). In another trial (n = 32), in which only a third of participants had traumatic brain injury), trial authors reported that seven of 17 (41.2%) people in the hypertonic saline group and 9 of 15 (60%) people in the mannitol group died by the end of stay in the ICU (<a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a>). Here, hypertonic saline did not reduce all‐cause mortality in people with acute traumatic brain injury (RR 0.69; 95% CI 0.34 to 1.39). We were able to pool data for two trials (n = 85) for mortality, but given the high loss to follow‐up in one, we presented data in three ways (per protocol, 'worst‐case' scenario for hypertonic saline and 'best‐case' scenario for hypertonic saline and there was no difference between groups at any time point (<a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a>;<a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a>). </p> </section> <section id="CD010904-sec-0101"> <h4 class="title">'Poor outcome' on the GOS</h4> <p>Using the method described above for mortality at six‐month follow‐up, and for the same reason, we present inconclusive results for this outcome based on pooling of two trials (n = 85). Again, there were no differences between groups; nor was there a difference in GOS reported in a smaller trial (n = 30) in which the GOS scale was dichotimised by grouping death and persistent vegetative status versus all other outcomes. </p> </section> <section id="CD010904-sec-0102"> <h4 class="title">Uncontrolled intracranial pressure</h4> <p>For the outcome of 'uncontrolled intracranial pressure', no meta‐analysis was feasible due to no uniform definition of 'uncontrolled intracranial pressure', and heterogeneity in reporting intracranial pressure changes. Therefore we reported these and all other results by individual trial. Essentially, trial results indicated that both treatments appeared effective compared with baseline, with some additional benefits for hypertonic saline, but the data are too few to be definitive and treatment selection might be individually based on sodium level and cerebral haemodynamics. </p> </section> <section id="CD010904-sec-0103"> <h4 class="title">Adverse effects</h4> <p>None of the trials systematically reported data on adverse effects, such as a rebound phenomenon, pulmonary oedema or acute renal failure during treatment. </p> </section> </section> <section id="CD010904-sec-0104"> <h3 class="title" id="CD010904-sec-0104">Overall completeness and applicability of evidence</h3> <p>This review set out to compare hypertonic saline against a potential range of other therapies. However, the only trials that met the inclusion criteria involved mannitol or mannitol with glycerol as a comparator. We thus have no evidence of how hypertonic saline compares to other intracranial pressure‐lowering agents. </p> <p>In addition, despite having found six trials, all were of small sample size and were powered (if powered at all) for short‐term outcomes. Heterogeneneity of modes of administration, dosages, outcome measurement and populations were so diverse as to make meta‐analysis difficult. Not all trials contained only participants with traumatic brain injury, and those from 'mixed' trials reported little about the source of participants' traumatic brain injury. Longer‐term (six‐month) follow‐up data were available from only three of the six trials. Clinical evidence is therefore insufficient at present to answer the objectives of the review. </p> </section> <section id="CD010904-sec-0105"> <h3 class="title" id="CD010904-sec-0105">Quality of the evidence</h3> <p>As stated above, sample sizes were small (287 people across six trials) and the outcome measures and methods used were heterogeneous. Data were missing for our primary outcome (mortality) as well as for 'poor outcome' on the GOS scale. Blinding of this intervention is often unfeasible, an inevitable weakness in such trials. A comment must also be made on the quality of the reporting of trials included within this review. None were reported in accordance with CONSORT standards (<a href="./references#CD010904-bbs2-0067" title="MoherD , HopewellS , SchulzK , MontoriV , GøtzscheP , DevereauxPJ , et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery2010;340:28‐55. ">Moher 2010</a>). Registration of trials (where extant) was retrospective; only one protocol was available. Results were equivocal and the quality of the evidence was low to very low, as these issues obliged us to downgrade for a variety of criteria. </p> </section> <section id="CD010904-sec-0106"> <h3 class="title" id="CD010904-sec-0106">Potential biases in the review process</h3> <p>The review is based on a thorough search of medical literature in English and Chinese, and we believe it is a complete compilation of the RCTs on this topic; however, we have made choices differently to that of other systematic review authors in the area. We have not incorporated data from one trial (<a href="./references#CD010904-bbs2-0036" title="VialetR , AlbaneseJ , ThomachotL , AntoniniF , BourgouinA , AlliezB , et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Critical Care Medicine2003;31:1683‐7. ">Vialet 2003</a>), used within other reviews focusing on mannitol (<a href="./references#CD010904-bbs2-0081" title="WakaiA , McCabeA , RobertsI , SchierhoutG . Mannitol for acute traumatic brain injury. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD001049.pub5] ">Wakai 2013</a>; <a href="./references#CD010904-bbs2-0082" title="WangK , SunM , JiangH , CaoXP , ZengJ . Mannitol cannot reduce the mortality on acute severe traumatic brain injury (TBI) patients: a meta‐analyses and systematic review. Burns &amp; Trauma2015;3(1):8. ">Wang 2015</a>), because of unreconciled discrepancies within the paper. We have (unlike the authors of <a href="./references#CD010904-bbs2-0039" title="BooneMD , Oren‐GrinbergA , RobinsonTM , ChenCC , KasperEM . Mannitol or hypertonic saline in the setting of traumatic brain injury: what have we learned?. Surgical Neurology International2015;6:177. [DOI: 10.4103/2152‐7806.170248] ">Boone 2015</a>, <a href="./references#CD010904-bbs2-0041" title="BurgessS , Anu‐LabanRB , SlavikRS , VuEN , ZedPJ . A systematic review of randomized controlled trials comparing hypertonic sodium solutions and mannitol for traumatic brain injury: implications for emergency department management. Annals of Pharmacotherapy2016;50(4):291‐300. ">Burgess 2016</a> and <a href="./references#CD010904-bbs2-0060" title="LIM , ChenT , ChenSD , CaiJ , HuYH . Comparison of equimolar doses of mannitol and hypertonic saline for the treatment of elevated intracranial pressure after traumatic brain injury: a systematic review and meta‐analysis. Medicine2015;94(17):e736. ">Li 2015</a>), excluded cross‐over trials. We maintain this is appropriate for our review question and focus on long‐term outcome. </p> </section> <section id="CD010904-sec-0107"> <h3 class="title" id="CD010904-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>There are two literature reviews (<a href="./references#CD010904-bbs2-0055" title="KamelH , NaviBB , NakagawaK , HemphillJC3rd , KoNU . Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta‐analysis of randomized clinical trials. Critical Care Medicine2011;39(3):554‐9. ">Kamel 2011</a>; <a href="./references#CD010904-bbs2-0068" title="MortazaviMM , RomeoAK , DeepA , GriessenauerCJ , ShojaMM , TubbsRS , et al. Hypertonic saline for treating raised intracranial pressure: literature review with meta‐analysis. Journal of Neurosurgery2012;116(1):210‐21. ">Mortazavi 2012</a>), of hypertonic saline for treating raised intracranial pressure, which included people with raised intracranial pressure from multiple aetiologies, which found that hypertonic saline was more effective than mannitol. </p> <p>One recent systematic review with meta‐analysis (<a href="./references#CD010904-bbs2-0074" title="RickardAC , SmithJE , NewellP , BaileyA , KehoeA , MannC . Salt or sugar for your injured brain? A meta‐analysis of randomised controlled trials of mannitol versus hypertonic sodium solutions to manage raised intracranial pressure in traumatic brain injury. Emergency Medicine Journal2014;31(8):679‐83. ">Rickard 2014</a>), found that both hypertonic saline and mannitol effectively lower intracranial pressure. Authors identified a trend favouring the use of hypertonic saline solutions in people with acute traumatic brain injury. However, this meta‐analysis included three trials that our review does not: two had cross‐over designs (<a href="./references#CD010904-bbs2-0007" title="BattisonC , AndrewsPJ , GrahamC , PettyT . Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Critical Care Medicine2005;33:196‐202; discussion 257‐8. ">Battison 2005</a>; <a href="./references#CD010904-bbs2-0028" title="SakellaridisN , PavlouE , KaratzasS , ChroniD , VlachosK , ChatzopoulosK , et al. Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries. Clinical article. Journal of Neurosurgery2011;114:545‐8. ">Sakellaridis 2011</a>). We maintain that the issue of 'carry‐over' effects in cross‐over trials confounds the estimates of the treatment effects and further, that it is impossible to assess the effect of hypertonic saline on death and neurological outcomes after traumatic brain injury in a cross‐over trial. This review also incorporated data from <a href="./references#CD010904-bbs2-0013" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. IchaiC , ArmandoG , OrbanJ C , BerthierF , RamiL , Samat‐LongC , et al. Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain‐injured patients. Intensive Care Medicine2009;35:471‐9. ">Ichai 2009</a>, which we have excluded. </p> <p>Another recent meta‐analysis (<a href="./references#CD010904-bbs2-0041" title="BurgessS , Anu‐LabanRB , SlavikRS , VuEN , ZedPJ . A systematic review of randomized controlled trials comparing hypertonic sodium solutions and mannitol for traumatic brain injury: implications for emergency department management. Annals of Pharmacotherapy2016;50(4):291‐300. ">Burgess 2016</a>), found no clinically important differences in mortality, neurological outcomes, and intracranial pressure reduction between hypertonic saline or mannitol in the management of severe traumatic brain injury. It included data from four trials that we have excluded (<a href="./references#CD010904-bbs2-0007" title="BattisonC , AndrewsPJ , GrahamC , PettyT . Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Critical Care Medicine2005;33:196‐202; discussion 257‐8. ">Battison 2005</a>; <a href="./references#CD010904-bbs2-0013" title="IchaiC . Re: Sodium Lactate versus Hypertonic Saline [personal communication]. Email to: H Chen 4 July 2013. IchaiC , ArmandoG , OrbanJ C , BerthierF , RamiL , Samat‐LongC , et al. Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain‐injured patients. Intensive Care Medicine2009;35:471‐9. ">Ichai 2009</a>; <a href="./references#CD010904-bbs2-0028" title="SakellaridisN , PavlouE , KaratzasS , ChroniD , VlachosK , ChatzopoulosK , et al. Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries. Clinical article. Journal of Neurosurgery2011;114:545‐8. ">Sakellaridis 2011</a>; <a href="./references#CD010904-bbs2-0036" title="VialetR , AlbaneseJ , ThomachotL , AntoniniF , BourgouinA , AlliezB , et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Critical Care Medicine2003;31:1683‐7. ">Vialet 2003</a>), but fundamentally, our conclusions are similar. Authors of <a href="./references#CD010904-bbs2-0076" title="SchwimmbeckF , VoellgerB , ChappellD , EberhartL . Hypertonic saline versus mannitol for traumatic brain injury: a systematic review and meta‐analysis with trial sequential analysis. Journal of Neurosurgical Anesthesiology2019;Sept 20; epub ahead of print:no pagination. ">Schwimmbeck 2019</a> performed a systematic review, meta‐analysis and trial sequential analysis comparing hypertonic saline and mannitol, concluding that there were, "indications that HS [hypertonic saline] might be superior to mannitol in the treatment of TBI [traumatic brain injury]‐related raised ICP [intracranial pressure]"; however, "there are insufficient data to reach a definitive conclusion, and further trials are warranted" (<a href="./references#CD010904-bbs2-0076" title="SchwimmbeckF , VoellgerB , ChappellD , EberhartL . Hypertonic saline versus mannitol for traumatic brain injury: a systematic review and meta‐analysis with trial sequential analysis. Journal of Neurosurgical Anesthesiology2019;Sept 20; epub ahead of print:no pagination. ">Schwimmbeck 2019</a>). Authors of <a href="./references#CD010904-bbs2-0047" title="GuJiajie , HuangH , HuangY , SunH , XuH . Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta‐analysis of randomized controlled trials. Neurosurgical Review2019;42(2):499‐509. ">Gu 2019</a> synthesised 12 RCTs including those excluded for reasons mentioned above. Searches did not capture <a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> or <a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a>. Once again, authors found a benefit that was not statistically significant for intracranial pressure control with hypertonic saline as compared to mannitol, but not enough to "lend a specific recommendation to select hypertonic saline or mannitol as a first‐line [treatment]"; all other outcomes (including function and mortality) were "close". </p> <p>In 2018, the European Society of Intensive Care Medicine (ESICM) reported the consensus and clinical practice recommendations on fluid therapy in neuro‐intensive care patients (<a href="./references#CD010904-bbs2-0070" title="OddoM , PooleD , HelbokR , MeyfroidtG , StocchettiN , BouzatP , et al. Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. Intensive Care Medicine2018;44(4):449‐63. ">Oddo 2018</a>). ESCICM recommendations in the area of hyperosmolar fluids for the management of elevated intracranial pressure guidelines are consonant with our findings, stating, "we suggest the use of mannitol or hypertonic saline solutions for reducing increased intracranial pressure (weak recommendation)". A weak recommendation was made when votes in favour or against (a mix of strong and weak options) reached the 80% threshold. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010904-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010904-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Six trials are included in this review" data-id="CD010904-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. Six trials are included in this review </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD010904-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1. Hypertonic saline vs mannitol, outcome: 1.2 mortality: 6 months" data-id="CD010904-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1. Hypertonic saline vs mannitol, outcome: 1.2 mortality: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Hypertonic saline versus mannitol, outcome: 1.3 GOS: poor outcome at 6 months (conventional dichotomisation)." data-id="CD010904-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Hypertonic saline versus mannitol, outcome: 1.3 GOS: poor outcome at 6 months (conventional dichotomisation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypertonic saline versus mannitol, Outcome 1 Mortality: short‐term." data-id="CD010904-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Hypertonic saline versus mannitol, Outcome 1 Mortality: short‐term.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references#CD010904-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypertonic saline versus mannitol, Outcome 2 Mortality: 6 months." data-id="CD010904-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Hypertonic saline versus mannitol, Outcome 2 Mortality: 6 months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references#CD010904-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypertonic saline versus mannitol, Outcome 3 GOS: poor outcome at 6 months (conventional dichotomisation)." data-id="CD010904-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Hypertonic saline versus mannitol, Outcome 3 GOS: poor outcome at 6 months (conventional dichotomisation). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references#CD010904-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010904-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/urn:x-wiley:14651858:media:CD010904:CD010904-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_t/tCD010904-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypertonic saline versus mannitol, Outcome 4 GOS: poor outcome at 6 months (death + persistent vegetative state vs all other disability categories )." data-id="CD010904-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Hypertonic saline versus mannitol, Outcome 4 GOS: poor outcome at 6 months (death + persistent vegetative state vs all other disability categories ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references#CD010904-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/media/CDSR/CD010904/image_n/nCD010904-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010904-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hypertonic saline compared with other intracranial pressure‐lowering agents for acute traumatic brain injury</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hypertonic saline compared with other intracranial pressure‐lowering agents for acute traumatic brain injury</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute traumatic brain injury </p> <p><b>Settings:</b> intensive care units </p> <p><b>Intervention:</b> hypertonic saline (between 3% and 7.5% solution) delivered by infusions </p> <p><b>Comparison:</b> all other intracranial pressure‐lowering agents eligible (but mannitol infusions the sole comparator within the included trials) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (RCTs)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Other intracranial pressure‐lowering agents (mannitol or mannitol with glycerol)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hypertonic saline</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> (short‐term) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>2 RCTs reported mortality in the short term, prior to discharge from hospital.</p> <p>Meta‐analysis was not possible.<br/> 1 RCT (n = 38) reported that 3/18 participants in the HTS group and 1/20 in the mannitol group died in the first 6 days following treatment, after which no further deaths occurred in the HTS group but a further 9 deaths occurred in the mannitol group prior to discharge. At this time point, there is a slight trend favouring HTS compared to mannitol (RR 0.33, 95% 0.11 to 1.02). </p> <p>The other RCT (n = 32, in which only a third of participants had TBI) reported that 7/17 (41.2%) participants in the HTS group and 9/15 (60%) in the mannitol group died by the end of stay in the ICU. Here, HTS did not reduce all‐cause mortality in people with acute TBI (RR 0.69, 95% CI 0.34 to 1.39). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not advisable to pool data due to difference in time of assessment and in populations</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> at 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35.6% risk (available case)</p> <p>35.6% risk (worst case for intervention, HTS)</p> <p>44.4% risk (best case for intervention, HTS)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30% risk (available case)</p> <p>40% risk (worst case for intervention, HTS)</p> <p>30% risk (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84 (0.46 to 1.55) (available case)</p> <p>RR 1.12 (0.66 to 1.89) (worst case for intervention, HTS)</p> <p>RR 0.67 (0.38 to 1.18) (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooling done with available, best‐case and worst‐case scenarios. In no case do results show a clear difference between groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Glasgow Outcome Scale: poor outcome</b> </p> <p>at 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66.7% risk (available case)</p> <p>66.7% risk (worst case for intervention, HTS)</p> <p>75.6% risk (best case for intervention, HTS)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72.5% risk (available case)</p> <p>82.5% risk (worst case for intervention, HTS)</p> <p>72.5% risk (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09 (0.82 to 1.44) (available case)</p> <p>RR 1.24 (0.97 to 1.58) (worst case for intervention, HTS)</p> <p>RR 0.96 (0.74 to 1.24) (best case for intervention, HTS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooling done with available, best‐case and worst‐case scenarios from two studies which supplied sufficient data. </p> <p>One study on children reported GOS non‐traditionally (defining 'poor outcome' as survival with any level of disability excluding persistent vegetative state and found no clear difference between groups </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Uncontrolled ICP</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>HTS vs mannitol</b> </p> <p>1 RCT reported a difference in the magnitude of ICP reduction and found both HTS and mannitol effectively and equally reduced ICP levels with subsequent elevation of CPP and CBF<i>,</i> although this effect was significantly stronger and of longer duration after HTS.<br/> Another 2 RCTs reported a difference in the ratio of uncontrolled ICP between the 2 groups, and the definition of uncontrolled ICP in these 2 RCTs differed, as did the time frames for data collection. 1 of these RCTs found both interventions to be effective, but added pretreatment factors need to be considered (e.g. serum sodium and haemodynamics). The 5th RCT found HTS to be more effective for increased ICP than mannitol but cautioned the benefit in this trial might be explained by "local osmotic effects". </p> <p>2 RCTs in which intervention was only given after CSF drainage had failed, reported the mean fall in ICP following a dose averaged over hundreds of episodes across 4‐6 days of treatment. Of these 2 RCTs, 1 found HTS to be superior to mannitol; the other found no clear difference between groups. </p> <p><b>HTS vs mannitol vs mannitol plus glycerol</b> </p> <p>A 6th RCT comparing HTS with mannitol and also with mannitol plus glycerol reported means and ranges of change within an hour following a single dose. They reported all 3 hyperosmolar agents (HTS, mannitol and mannitol plus glycerol) as effective, but HTS was slightly superior, effecting a greater change in reducing ICP, and more quickly, than other agents, while at a lower dose. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287</p> <p>(6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It is not possible to pool these data because of variations in timings and ways of reporting ICP </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>A rebound phenomenon</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>None of the RCTs reported on this outcome systematically, although it is mentioned in passing as potentially affecting those treated with mannitol in 1 RCT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was reported in just 1/4 RCTs available.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary oedema</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute renal failure</b> during treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CPP:</b> cerebral perfusion pressure; <b>CSF:</b> cerebrospinal fluid; <b>HTS:</b> hypertonic saline; <b>ICP</b> : Intracranial pressure: <b>ICU:</b> intensive care unit; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>TBI:</b> traumatic brain injury </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded for imprecision (low number of participants), risk of bias and indirectness (1 trial included a mixed population of whom only a third had TBI).<br/> <sup>b</sup>We downgraded for imprecision, inconsistency and risk of bias.<br/> <sup>c</sup>We downgraded for imprecision, indirectness and risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hypertonic saline compared with other intracranial pressure‐lowering agents for acute traumatic brain injury</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010904-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data collected within studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0001" title="CottenceauV , MassonF , MahamidE , PetitL , ShikV , SztarkF , et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. Journal of Neurotrauma2011;28:2003‐12. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 2 March 2015. SoustielJF . Comparison of effects of equiosmolar doses of mannitol and hypertonic saline [personal communication]. Email to: H Chen 6 May 2015. ">Cottenceau 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0002" title="FranconyG , FauvageB , FalconD , CanetC , DilouH , LavagneP , et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Critical Care Medicine2008;36:795‐800. PayenJ‐F , FauvageB , CanetC , LavagneP , FalconD . Comparing the effects of mannitol and of hypertonic saline solution on post traumatic intracranial hypertension: a study with direct individual benefit [Effets comparés du mannitol et du sérum salé hypertonique sur l’hypertension intracrânienne post‐traumatique: Etude avec bénéfice individuel direct.]. Unpublished document [sent to H Chen by Dr J‐F Payen May 2002]. ">Francony 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0003" title="HarutjunyanL , HolzC , RiegerA , MenzelM , GrondS , SoukupJ . Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients ‐ a randomized clinical trial [ISRCTN62699180]. Critical Care2005;9:R530‐40. ">Harutjunyan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0004" title="CTRI//04/006829 . A comparative study of 3% hypertonic saline and 20% mannitol in the treatment of refractory posttraumatic intracranial hypertension. Available online (ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=10708&amp;EncHid=&amp;modid=&amp;compid=%27,%2710708det%27) (accessed 8 December 2017). JagannathaAT . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Email to: J Dennis 27 December 2017. JagannathaAT , KamathS , DeviI , RaoUGS . The salt versus sugar debate: Urinary sodium losses following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury. Clinical Neurosurgery. 2016; Vol. 63:212. JagannathaAT , SriganeshK , DeviBI , RaoGS . Urinary sodium loss following hypertonic saline administration curtails its superior osmolar effect in comparison to mannitol in severe traumatic brain injury: a secondary analysis of a randomized controlled trial. Journal of Neuroanaesthesiology and Critical Care2018;5(3):164‐7. JagannathaAT , SriganeshK , DeviBI , RaoSU . An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. Journal of Clinical Neuroscience2016;27:68‐73. [DOI: 10.1016/j.jocn.2015.08.035] ">Jagannatha 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0005" title="KumarSA , DeviBI , ReddyM , ShuklaD . Comparison of equiosmolar dose of hyperosmolar agents in reducing intracranial pressure‐a randomized control study in pediatric traumatic brain injury. Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery2019;35(6):999‐1005. ">Kumar 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010904-bbs2-0006" title="PatilH , GuptaR . A comparative study of bolus dose of hypertonic saline, mannitol, and mannitol plus glycerol combination in patients with severe traumatic brain injury. World Neurosurgery2019;125:e221‐8. ">Patil 2019</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline measures</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, source of injury)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, weight)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, weight)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, source and type of injury, duration from injury to hospital ) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data (age, gender, source and type of injury, duration from injury to EVD insertion) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Demographic data apparently collected, but not reported. Source of injury</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data included: initial GCS score; CT scan studies analyzed using Marshall criteria considering presence of<br/> basal cisterns compression, midline shift &gt; 5mm, and lesions &gt; 25cm3 in volume. Lesions were categorized into two subgroups: diffuse<br/> and focal </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: GCS score; 'preserved cerebral autoregulation'; 'injury to studied treatment (time in days), diagnosis (not all participants had TBI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: initial GCS score; SAPS, 'basic illness', brain infarct or not) etc; "simplified acute physiology score" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: Initial GCS score; GCS score post‐resuscitation; median GCS score at inclusion to trial; Predominant lesion on CT scan </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline including: Post‐resuscitation GCS; motor score; Marshal CT grade; predominant lesion in CT scan </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurological condition data at baseline: GCS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICP data collected during trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fall in ICP (mean and SD before infusion, after 30 min, after 120 min, comparisons made using repeated measures model of ANOVA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fall in ICP reported as percentage decline from baseline values (mean ± SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fall in ICP (mean and range before infusion, terminating infusion, after 10 min, 30 min, 60 min); percentage decline calculated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute values of ICP; response to individual boluses of agents (means and SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean reduction in ICP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimum and maximum ICP (mmHG) at 1 hr</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICP responses also compared based on analysis of percentages of the baseline (instead of absolute values) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time course of ICP changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time required to reduce ICP below 20mm Hg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean duration of ICP monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maximum change in ICP in percentage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 1: hours of ICP &gt; 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of ICP fall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 h mean ICP monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dose and time required to reduce ICP below 15mm Hg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Numbers of ICP elevations during average monitoring duration of 3.7 to 3.8 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 h mean ICP monitoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICP tracings</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time required to achieve ICP &lt; 20 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean numbers of raised ICP episodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of time ICP was maintained at &lt; 20 mmHg in a given day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>'Effective' doses/'ineffective' doses (as regards ICP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean number of doses per day; instances of refractory ICP (mean (SD)) (defined as persistently elevated ICP despite 3 consecutive doses) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other interventions recorded</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgical intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inotrope intervention/duration of inotrope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery for evacuation of EDH, depressed skull fracture or contusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbiturate intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ionotropes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSF drainage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CSF drainage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other data measured in ICU</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Common measures</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MAP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CPP</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CVP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum Na</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cerebral metabolic rate of glucose (CMRGlc (mg/100 g/min))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum osmolarity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluid balance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluid balance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemoglobin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hematocrit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hematocrit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hematocrit</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of CSF drained</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of CSF drained</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean (SD) duration of ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures unique to individual trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global CBF (mL/100 g/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preserved cerebral autoregulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AVDO<sup>2</sup>, AVDGlc and AVDLct contents were calculated allowing the determination of CMRO<sup>2</sup>; CMRGlc and CMRLct </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum chloride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SpO<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood urea nitrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum creatinine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shear Rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood flow velocities/arterial blood pressure (systolic, mean and diastolic)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brain tissue oxygen tension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urine output (vol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arterial PH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PaO<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of stay data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days on ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of ICU stay/ duration of overall hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of ICU stay/ duration of overall hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality/ neuro outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In ICU, GCS score following interruption of sedative drugs. Neurological outcome at 6 months: GOS as 'good recovery', 'moderate disability', 'severe disability', 'persistent vegetative state' and 'death' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality at the end of stay in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In‐hospital mortality plus GOS scores/mortality at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GOS scores at 6 months (unconventionally dichotomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GCS at one hour after one dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AVDGlc:</b> Arterial jugular differences for glucose; <b>AVDLct</b> : Arterial jugular differences for lactate; <b>AVDO</b><sup>2</sup>: Arterial jugular differences for oxygen; <b>CBF</b> : cerebral blood flow; <b>CMRGlc</b> : cerebral metabolic rate of glucose; <b>CMRLct</b> : cerebral metabolic rate of lactate; <b>CMRO<sup>2</sup> </b> : cerebral metabolic rate of oxygen; <b>CPP</b> : cerebral perfusion pressure; <b>CSF</b> : cerebrospinal fluid; <b>CVP</b> : central venous pressure; <b>CT</b> : computed tomography; <b>EVD</b> : extraventricular drain; <b>GCS</b> : Glasgow Coma Scale; <b>GOS</b> : Glasgow Outcomes Scale; <b>ICH</b> : intracranial hypertension;<b>ICP</b> : intracranial pressure; <b>ICU</b> : intensive care unit; <b>MAP</b> : mean arterial pressure; <b>NICU</b> : neuro‐intensive care unit; <b>PaCO<sup>2</sup> </b> : partial pressure of carbon dioxide in arterial blood; <b>PaO<sup>2</sup> </b> : partial pressure of oxygen in arterial blood; <b>SAPS</b> : simplified acute physiology score; <b>SD</b> : standard deviation; <b>SPO2</b> = peripheral oxygen saturation </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data collected within studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/full#CD010904-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010904-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypertonic saline versus mannitol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality: short‐term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mortality within 6 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mortality at discharge from ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Mortality at discharge from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Mortality at 6 months' follow‐up (available data for Jagannatha)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.46, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Mortality at 6 months' follow‐up (worst case for HTS data for Jagannatha)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.66, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Mortality at 6 months' follow‐up (best case for HTS data for Jagannatha)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 GOS: poor outcome at 6 months (conventional dichotomisation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 GOS 6 months (available data Jagannatha)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.82, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 GOS 6 months (worst case for HTS data for Jagannatha)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.97, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 GOS 6 months (best case for HTS data for Jagannatha)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 GOS: poor outcome at 6 months (death + persistent vegetative state vs all other disability categories ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 GOS: poor outcome at 6 months (unconventional dichotomisation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypertonic saline versus mannitol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010904.pub3/references#CD010904-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010904.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010904-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010904-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD010904-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010904-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010904-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010904-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010904-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010904\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010904\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010904\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010904\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010904\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010904.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010904.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010904.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010904.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010904.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728264921"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010904.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728264925"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010904.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec0419fc1f46e',t:'MTc0MDcyODI2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 